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INTRODUCTION 
 
Pregnancy  is  time  when  serial  metabolic  changes  in  mother  are  carefully  regulated  
so  as  to  provide  optimum  substrate  to  both   mother   and  foetus.  Subtle  perturbation  in  
maternal  metabolism  can  have  implication  not  only  for  index  pregnancy  but  also  for the  
future generation. 
 
Diabetes is one of the commonest medical  complication  of  pregnancy.  Patients  can  
be  separated  into  those  who were  known  to  have  diabetes  before  pregnancy (overt) and 
those diagnosed  during  pregnancy (gestational). 
 
GDM  is  defined  as  carbohydrate  intolerance of  varying  severity  with  onset  or  first  
recognition  during  pregnancy.   
 
GDM  as  a  concept  began  in   1964  when  O’ Sullivan  and  Mahan  performed  a  
100gm  3 hour  GTT on 752  pregnant  women  with  atleast  two  values above  two  standard  
deviation. 
 
GDM    is  risk  factor  for  the  mother  and  the  foetus.  The  risk  increase  
proportionally  to  the  maternal  blood sugar  concentration  along        a  glycaemic  continuum.  
Various  screening  and  diagnostic  tests  are  used.  The  need  to  screen  the GDM  as  a  risk  
factor  in  the  whole  population      of  pregnant  woman  has  lead  us  to  propose  the  use  of  
simple,  universally  applied  test  constituted  by  glucose  challenge  test. 
 
SCREENING  FOR  ABNORMAL GLUCOSE  TOLERANCE 
IN  PREGNANCY 
 
The purpose of screening is to subject minimum number of women          to  the 
diagnostic test – the oral Glucose Tolerance Test  (high specificity) and yet to detect as many as 
possible cases (high sensitivity). Ideally screening should be performed at the initial visit in order 
to detect the rare, previously  undiagnosed cases of subclinical diabetes mellitus. This is 
particularly    justifiable in some  groups (ie) Impaired Glucose Tolerance / Gestational Diabetes 
Mellitus in a previous pregnancy or in high  risk women such as   older Indian women with 
multiple potential diabetic features, screening test  should be repeated again even if an earlier 
test is negative. As a compromise 28 weeks is usually considered an appropriate time as most 
cases should be diagnosed by then and there  may  be an  opportunity  still  to  influence  the  
outcome. 
       
Screening tests are means by which patients are selected for definitive testing. screening 
tests should be well defined, clearly administered,  inexpensive, reproducible and have high 
sensitivity. It need not have high specificity  demanded  of  the  diagnostic  test. 
 
Tests  of  carbohydrate  intolerance  during  pregnancy  
 Simple screening test, abnormal value include fasting plasma glucose   >105 mg%  and  
random 2 hours  / post prandial glucose 120 mg% 
 
 Recommended loading test for screening, 50 gm glucose load given  orally  at  random, 
abnormal  is  >140 mg% after 1 hour. 
 
  Other screening  tests  for abnormal  glucose  tolerance 
 
GLUCOSURIA AS A SCREENING TEST 
 
Commonly employed screening test for detection of glucose     intolerance. But during 
pregnancy renal threshold for glucose is often lowered partly due  to an 8 fold increase in 
glomerular filtration of  glucose and          partly  to  an  intermittent  tubular  defect  in  glucose  
reabsorption. 
 
The specificity  can be increased by defining significant glycosuria as    that which occurs 
in second fasting specimen. The patient  is instructed to      void on waking up. Half an hour later 
while still fasting,  she voids again and     the specimen is tested for glucose. In normal 
pregnancy, fasting  blood     glucose is low so glucose at that time cannot be due to low renal 
threshold      and is thus significant. Women with renal glycosuria during  pregnancy are         at a 
high risk of premature delivery  (25% incidence) and the development         of fetal macrosomia 
(7%) in some cases renal glycosuria during pregnancy        is  a  manifestation  of  renal   tubular  
damage  caused   by   chronic nephritis. 
STOVER (1982) found glucosuria in fasting specimen to be a true   indicator of  glucose  
intolerance  during  pregnancy. 
 
FASTING GLUCOSE STUDIES 
  
In fasting states there is accelerated starvation in the mother. After an overnight fasting of 
12 hour, the level of glucose in pregnancy  is significantly lower compared to non pregnant state 
(ie) an exaggerated lowering of   circulating  glucose  concentration. 
 
METZGEN et al reported that plasma glucose concentration after an overnight fasting 
was approximately 10 mg% lower in pregnant women and     that glucose  fall by additional 8 – 10 
mg% in the pregnant but not in               non-pregnant, when both groups postponed breakfast for 
6 hours. When       there  is  fasting   plasma   glucose   value  >105  mg%, it suggests glucose  
intolerance. 
 
O’SULLIVANS GLUCOSE CHALLENGE TEST 
 
O’ Sullivan’s 50 gm oral glucose challenge test is the best screening     test with excellent 
sensitivity and specificity of 79% and 87% respectively (GABBE et al 1991). The 1990 Chicago 
conference on gestational diabetes recommended that all pregnant women should  be screened 
using a             50gm  oral glucose challenge test between 24  to  28 weeks of gestation    without  
regard to the time of the day or last meal and that a plasma value           at 1 hour exceeding 140 
mg/dl be used as  the cutoff for performing                  the diagnostic 100gm oral glucose 
tolerance  test. Women with previous     history of GDM may benefit from earlier screening. If 
screening in early pregnancy  yields a normal  result,  subsequent  screening  should  be  
performed  at  24  to 28 weeks. 
 
According to ACOG (1994) the sensitivity of screening may be     improved by  using a 
130 mg/dl threshold rather than 140 mg /dl to              define an  abnormal response to 50 gm 
test. Use of lower threshold  value      may  increase detection of abnormal glucose tolerance 
from 90% to nearly  100% but at the expense of subjecting 25% of pregnant  women  to the               
3  hour  test.  Thus  the  threshold  for  further  testing  be  chosen  based  on goal  of  screening. 
 
GLUCOSE  POLYMER  CHALLENGE  TEST 
 
Glucose polymer is an inexpensive commercially available glucose  saccharine mixture 
containing 3% glucose, 7% maltose, 55% maltotriose         and 85% polysaccharides. Its osmotic 
load is one fifth that of glucose            and  has been associated with gastrointestinal symptoms. 
A moderate        level  of agreement  between  the  results  of  3 hour  GTT has  also  been 
demonstrated. 
GLYCATED BLOOD PROTEINS IN THE DIAGNOSIS OF GDM 
 
Glycated Hb% and other proteins have been investigated as screening test  for GDM. 
Glycation is the slow and almost irreversible binding of        glucose or a phosphorylated sugar to 
Hb or other blood proteins. Because          it is dependent on concentration of reactants and 
because the red cell concentration of glucose approximates that in extracellular  fluid glycated      
Hb% has been investigated  as  a  diagnostic  test  for  non gestational       related  diabetes. 
 
GDM  however may not present with the same constant elevation of  blood sugar levels 
as in non pregnant state. Gravid women with GDM have fasting  blood sugar level that is low. 
Because of increased erythropoisis,         red  blood  cells are younger in pregnancy, Hb is less 
glycated. Hormonal     milieu changing rapidly from relative insulin sensitivity to that of insulin  
resistance as  pregnancy progresses,  a  measure  of chronic hyperglycemia  such  as  glycated  
Hb%  may   not  be  effective  in  GDM. 
 
SHAH et al measured  Hb A1C  using  ion  exchange chromatography  and applied 
NDDG criteria for GDM in a group of patients. The results       showed 27% sensitivity for glycated 
Hb% in the identification of GDM                 in risk group. Hb A1C >8.8% taken as abnormal. 
These data  do  not          support  the  use  of  Hb  A1C  as  screening  test  for  GDM. 
 
Other glycosylated plasma proteins that are used as potential marker     are glycosylated 
albumin and fructosamine. It is commonly used in clinical investigation because it models the 
physiological events after a meal               and  is  easily  administered. The  national diabetes 
data group (NDDG)  criteria  for diagnosis  of  GDM  has  been  recommended by  American 
diabetes association. 
 
  
O’Sullivan 
(whole blood)
 
NDDG 
(P) 
 
Carpenter 
Coustan(P) 
 
Fasting 
 
90 (5) 
 
105 (5.83) 
 
95 (5.28) 
 
I hr. 
 
165 (9.17) 
 
190 (10.56) 
 
180 (10) 
 2 hr. 
 
145 (8.06) 
 
165 (9.17) 
 
155 (8.61) 
 
3 hr. 
 
125 (6.94) 
 
145 (8.06) 
 
140 (7.78) 
 
If more than  or equal to 2 values are met or exceeded – diagnosis          of  GDM is 
made. 
 
DETERMINANTS  OF ABNORMAL  GLUCOSE  TOLERANCE  IN  PREGNANCY 
 
The various risk factors associated with abnormal glucose tolerance        in  pregnancy 
are  : 
 
 Age 
 Ethnicity 
 Obesity (>200pounds or 15% of non pregnant ideal body weight) 
 Positive family history of diabetes 
 Poor reproductive history  
(>3 spontaneous abortions in the first or second trimester) 
 
 History of prematurity 
 History of stillbirth 
 History of delivery of large infant 
 History of unexplained neonatal death 
 History of traumatic delivery with associated neurological disorder  
in  the  infant 
 
 History of congenital anomaly 
 History of diabetes in previous pregnancy 
 History of preeclampsia in a previous pregnancy, chronic hypertension 
 
 Preeclampsia in a multipara 
 Recurrent severe moniliasis or UTI 
 Polyhydramnios 
 Glycosuria 
 
ETHNICITY 
     
The prevalence of abnormal glucose tolerance is highly dependent          on  ethnicity 
(HADDEN 1985 BEISCHER et al 1991). Compared with European women, the prevalence rate is 
approximately eleven fold in women from      Indian  sub continent (DORN HORST et al 1992) 
 
AGE AND OBESITY 
 
Increasing age and obesity (BMI>26) are independent risk factors for abnormal glucose 
tolerance (O’SULLIVAN et al 1973; MARESH & BEARD 1989; ROSEMAN et al 1991) 
 
FAMILY HISTORY OF DIABETES 
 
Family history of diabetes either in first degree or second degree   relatives is an 
important risk factor for developing abnormal glucose tolerance   (5 –10 times  risk  greater  than  
for  children  with  non diabetic  parents). 
 
The risk for IDDM is found to be inherited asymmetrically from the   mother and father. 
 
GARNER et al (1995) observed when the mother had IDDM, 1-3% of offsprings 
developed diabetes whereas when the father had IDDM, 6% of offsprings developed diabetes 
and when both parents had IDDM, 20% of offspring developed diabetes. The greatest risk of the 
offspring developing diabetes occurs when one or both parents developed the disease  before         
the  age  of 40. 
 
Hence a history of IDDM in the father is of greater predictive value       than  in the mother 
and even greater when a sibling is diabetic. A family      history    in  grandparents is  less 
significant. 
FOSTER (1994) found that 40% of siblings and one third of offsprings     of women with 
NIDDM develop abnormal glucose tolerance or obvious   diabetes. 
 
FETAL & PERINATAL WASTAGE 
 
Pregnancy outcome is highly dependent on maternal glycemic control throughout the 
pregnancy. Several studies have shown  that spontaneous abortion is associated with poor 
glycaemic control during the first trimester, GREENE et al (1989), MILLS et al (1988b). 
KARLSON & KJELLMER 1972 demonstrated an inverse relationship between mean ambient 
glucose levels during third trimester and perinatal mortality. HANSON & PERRSONN (1993)    in 
the Swedish study reported the incidence of unexplained stillbirths to             be between 0.4 to 
3% and the incidence of preterm labour in classes                     B to F  diabetes  as  25%. 
 
PERINATAL MORBIDITY AND MORTALITY 
 
This is  increased  due  to  the occurence  of  following  neonatal  complications. 
 
(a) Neonatal hypoglycaemia:   
Defined by the ACOG (1995) as plasma glucose < 35 mg/dl (1.7mmol/l) in a term fetus. It 
occurs due to hyperinsulinaemia and suppression of endogenous glucose production by 
decreasing gluconeogenesis and glycogenolysis which occurs despite an abundance of 
glycogen stores in liver and myocardium. Hyperinsulinaemia also leads to  increased 
peripheral glucose utilisation. The peak age of onset  of hypoglycaemia is at 1 to 1.5   
hours of age. The factors mainly   protective against foetal hypoglycaemia is the optimal 
control of  maternal hyperglycaemia especially during  the third trimester and  during  
labour. It has been shown that a  mean maternal plasma glucose >105 mg/dl during the  
last 4 hrs. of labour in a diabetic  mother  leads  to  higher  incidence     of   neonatal  
hypoglycaemia. 
 
(b) Hypocalcaemia :  
About 25% of the infants of diabetic mothers may present with serum calcium <7mg/dl 
(1.6mmol/l). The mechanism remains under investigation, but it has been suggested that 
a state of relative maternal hyperparathyroidism play a role. Asphyxia and prematurity 
operating through elevated cortisol induces vitamin - D antagonism at the intestinal level. 
Respiratory distress and fetal metabolic acidosis may result in calcium being shifted from 
intracellular to extra cellular pools and reversal  of  this shift during the correction of 
acidotic event may produce hypocalcemia. The peak age of onset hypocalcaemia is         
the second  or  third  day  of life.  Hypomagnesemia  may coexist. 
(c)          Birth injury : 
 
Some of the birth injuries in macrosomic infants include Erb’s  palsy, fractured clavicle, 
facial paralysis, phrenic nerve injury, intracranial haemorrhage in the form of intra 
cerebral bleeding or subdural  hematoma. 
 
(d)          Respiratory distress syndrome :  
RDS has been observed in about 5% of the infants. In vitro studies indicate that insulin 
antagonises the stimulatory effects of cortisol     on fibroblast  to  induce the synthesis 
of fibroblast – pneumocyte factor (FPF) which in turn inhibits type II cells and 
phosphatidyl  choline production. But several reports have challenged the concept  of 
diabetes altered lung function. Gestational age, rather than overt diabetes, is likely the 
most significant factor governing the development of  RDS (BERKOWITZ  et  al 1996). 
 
(e)          Neonatal hyperbilirubinaemia :  
The pathogenesis of hyperbilirubinemia is uncertain. Factors implicated  are  
prematurity  and  polycythemia  with  hemolysis.    
 
(f)          Neonatal polycythemia and hyperviscosity syndrome :  
This is diagnosed when the neonatal hematocrit exceeds 65%        and has been 
observed  in as many as 40% of infants of diabetic mothers (SALVESEN et al 1992). It 
occurs probably due to   excessive production of erythropoietin. Diabetic pregnancy 
may also contribute. The resultant hyperviscosity may induce congestive heart failure 
and vascular thrombosis accounting for the increased risk       of  renal  vein  
thrombosis  in  these  infants. 
 
(g)          Fetal cardiac hypertrophy :  
Fetal hyperinsulinaemia may lead to hypertrophic cardiomyopathy  that  occasionally  
progresses  to  congestive  cardiac  failure        
(GANDHI et al 1995). 
 
(h)          Long term sequelae: 
a. Growth – The growth rate, height and development as they relate to obesity are 
excessive during childhood and early adulthood which suggests an important 
influence of the diabetic intrauterine environment. 
 
 Glucose hemostasis – Because of genetic and environmental factors, glucose 
tolerance is more likely to be abnormal in  these offsprings. One third of 
offsprings of NIDDM develop abnormal glucose tolerance  or  obvious  
diabetes (FOSTER 1994). 
 
 Neurologic and psychological development : Offspring of high risk pregnancy 
often have neurologic deficits which are relatively minor but which may be a 
significant cause of morbidity. Possible reasons for these are birth trauma, 
metabolic abnormalities during and after gestation, cerebral dysfunction etc. 
 
CONGENITAL MALFORMATIONS 
 
HENRIQUES et al (1991) found that diabetes is not associated  with increased risk for 
fetal chromosomal abnormalities. ROSSEN et al 1994 demonstrated the incidence of major 
malformations in women with overt  diabetes  is  5 – 10%. 
 
FETAL MACROSOMIA 
 
WILLIAM et al 1986 have shown that the incidence of macrosomia      rises significantly 
when mean maternal blood glucose concentrations exceed  130 mg/dl. PETTIT et al found a 
direct relationship  between the maternal  plasma glucose 2 hours after a 75 gm oral glucose  
challenge and  the   likelihood   of   the   birth  of  a  large  baby. 
 
PREVIOUS  HISTORY OF ABNORMAL GLUCOSE TOLERANCE 
 
Women with history of abnormal glucose tolerance are at greatly increased  risk of 
diabetes in future pregnancies (PHILIPSON & SUPER       1989, CARPENTER et al 1996 and 
CURET et al 1996) observed that women diagnosed to have abnormal glucose tolerance have 
pre-existing alterations       in insulin economy and BERKUS et al 1996 concluded that  
gestational   diabetes was likely to be maturity onset diabetes rather than a distinct       diabetic 
state  due  to  pregnancy.  
 
HYPERTENSION 
 
 SUHONEN and TERANO 1993 studied hypertension and pre-eclampsia   in women with 
gestational glucose intolerance and found an increased   incidence in these patients. SOLOMON 
et al 1994 have found that glucose intolerance  was  an  important  predictor  of  hypertension  in  
pregnancy. 
 
INFECTIONS 
 
  STAMLER et al 1990 found an increased rate of infections morbidity         in antenatal 
patients with abnormal glucose tolerance. 80% had candida vaginitis, pyelonephritis, skin and 
respiratory infections and pelvic puerperal infections. 
REVIEW OF LITERATURE 
 
O’SULLIVAN and  MAHAN  in  their  classical  study  of  1964  analysed  glucose  
response  over  3  hours  to  a  100 gm  oral  glucose  challenge  in  752  healthy   pregnant  
women  which  yields  values  representing   the  mean  plus  or  minus  two  standard  deviation  
in  the  fasting  state  and  at  1,2  & 3 hours  by  arbitrarily  declaring  abnormal  carbohydrate  
handling  as  that  exceeding  2.5  D  above  the  mean  on  2  or  more  values,  2.5%  of  the  
population  was  defined  as  having  GDM.    
 
Diagnosing  GDM  and  instituting  aggressive   management  of  the  mother  are  
intended  to  reduce  or  eliminate  the  perinatal,  neonatal  and  long  term  complication  in  the  
offspring.  O’Sullivan  and  Mahan’s  criteria was  too  lax  for   the  identification  of  people  at  
risk  for  perinatal  morbidity  associated  with  carbohydrate  intolerance.  The  original  criteria  
was  based  on  whole-blood  determination  of  glucose  by the  Somogyi  method.  
 
This  was subsequently  modified  by  National Diabetes Data Group       to  use  a 
conversion  factor  of 1.14  represent  plasma  glucose  determination     by  glucokinase  
technique. Technical  modification  of  that  conversion  have  been  recommended  by  Carpenter  
and  Coustan  as  being  more  representative  of  the  true  plasma  glucose  determination.  This  
modification  results  in  a  lowering  of  all  glucose  levels in  the  3  hours  glucose  tolerance  
test,  thus  increasing  the  sensitivity  of  the  test.  By  using  the  lower  modified  criteria,  
overall  incidence  of  GDM  is  increased  by  56%. Data  on  the  modified  criteria  presented  at  
the  4th  international  workshop  on  gestational  diabetes  infants  of  women  meeting  these  
lower  criteria  are  at  a risk for  perinatal  morbidity  including  macrosomia.  Hence, Carpenter 
and  Coustan  criteria  was  adopted  for diagnosis. 
 
The  4th  international  workshop  on  gestational  diabetes  defined  cut  off  values  for  
the  controversial  75g  oral  GTT  in  pregnancy.  The  cut  off  values  were  arbitrarily  defined  
based  on  the  mean  plus  1.5  SD  of  the  OGTT  values  in  a  study  of  over  3500  patients.  
Greater  experience  in  the use  of  75gm  oral  GTT  and maternal  and  infant   outcomes  data  
will  be  needed to  define   better  cut  off  values  for  this  test.  Data  are  becoming  
increasingly  available  to  suggest   that  a  single  abnormal  value on  GTT  may  predict  
perinatal  outcome.  Tallerigo  et  al  examined  the  neonatal  outcome in  249  women  and  
found that  2  hours  plasma  glucose  concentration  after  a  100gm  OGTT  significantly  
correlated  with  the  infant’s  birth  weight. 
 
Because  of  lack  of  reproducibility  of  the  glucose  tolerance  test,  together  with  the  
discrepancies  in  the  number  of  abnormalities   much   effort  has  gone  into  establishing  
simpler  diagnostic  criteria  for  GDM. Neither  glycated  haemoglobin  nor  fructosamine  is  
sufficiently  sensitive  for  identification  of  women  with  GDM. 
 
Random  glucose  testing  and  use  of  reflectancemeters  lack  the  sensitivity  for  
adequate  identification  of  women  at  risk  for  GDM. The  best  screening  test  appears  to  be  
the  50gm, 1hour  glucose  challenge  test.     The  second  international  workshop  conference  
on  GDM  concluded  that     all  pregnant  women  should  be  screened  for  GDM.  A  1  hour  
plasma  glucose  determination  in  excess  of  140gm/dl  (lower  by  Carpenter  Coustan  criteria)  
constitutes  a  positive  screen  and  requires   the  performance  of  a traditional  100gm OGTT  
for  confirmation  of  GDM. 
 
Nayeor  et  al  evaluated  data  on  over  3000  pregnant  women  and  developed  a  
scoring  system  to  determine  the  risk  of  GDM  based  on  age, BMI and race. The  American  
diabetes  association  position  statement  suggest  that  it  is  not  cost  effective  to  screen  
women at  low  risk.  This  new policy  has  been  controversial,  however,  with  some  
suggesting  that 10%  of  patients  with  GDM  would  be  missed  if  all  women  were  not  
screened. 
 
Glucose traditionally   has  been  used  as  the  marker  for  GDM  because of  its  ease  
of  measurement  and  test  reproducibility.  It  is  now  clear  that alteration  in  insulin  secretion,  
insulin  sensitivity  and  carbohydrate,  fat and amino acid  metabolism   are  all  intrinsic  
abnormalities  in  the  state  that  we  have  to  accept  as  GDM. Developing  more  sensitive 
indices  for  prediction  of  perinatal  morbidity   may  require  either  intensification  of  glycaemic  
criteria  or the  inclusion  of  more  sophisticated  metabolic  measurements. 
 
The  second  international  workshop  on  gestational  diabetes  in  1985  defined  
gestational  diabetes as  “carbohydrate  intolerance  of  varying     severity  with  onset or  first  
recognition  during  present  pregnancy”  and  this   is  the  current  widely  accepted  definition  of  
GDM. 
 
Gabbe  in 1980  in  his  masterly  review titled  “management  of  diabetes  in  pregnancy 
;  six  decades  of  experience”  traced  the  history  of  management  of  this condition  and  
identified  four  distinct  periods  as     shown  below : 
 
AIM  OF  CARE  
 
 1921 – 1940  Avoid  ketoacidosis 
 1941 – 1970  Team  care / Early  delivery 
 1971 – 1976  Foetal  Surveillance 
 1976 – 1992  Aim  for  normoglycemia 
 
DAVID  STAMILIO  et  al  in  January  2004  performed  a  retrospective  cohort  study  of  
1825  eligible  pregnant  women  among  a   cohort  of  1998  patients.  Patients  were  screened  
for  GDM  with  the  1 hour 50gm  GCT  at  24 - 28  gestational  week.  False  positive  GCT  was  
defined  as  a  result greater  than  or  equal  to 135  mg./ dl  followed  by  a  normal  3  hour GTT.  
Comparison  was  made  between  negative  GCT and   false  positive  GCT     for  a  composite  
perinatal  outcome  variable  that  included foetal  macrosomia,  antenatal  death,  shoulder  
dystocia,  chorioamnionitis,  preeclampsia,  NICU  admission,  caesarean  delivery   and  
postpartum  endometritis.  The  results  were  164  patients  with  a  false  positive  GCT  and  50  
patients  with  GDM.  The  false  positive  GCT  cohort  on  average  was  older,  was of a  higher  
parity,  had  a  higher  BMI  and  more frequently  had  chronic  hypertension,  sickle  cell trait  
and  elevated   midtrimester  HCG.  False  positive  GCT  was  more  frequently  associated  with 
adverse  perinatal  outcome  including  composite  perinatal  out come  (Odds ratio   5.96),  
macrosomia  more  than   4500 g  (OR 3.66), antenatal  death (OR 4.61), shoulder  dystocia  (OR  
2.85), endometritis  (OR 2.18),  and  caesarean  delivery  (OR 1.76). 
 
The  university  of  Pennsylvania  institutional  review  board  approved  this  study.  So  
patient  with  a  false  positive  GCT  could  benefit  from  additional  therapies  such  as  more  
intensive  foetal  monitoring,  nutritional  counselling  or  a  diabetic  diet.  The  results  of  this  
study  suggests  that  having  a  false  positive  GCT  is  an  independent risk  factor  for  adverse  
perinatal  outcome.  
 
Rey  et  al  reported  that  patients  with  an  abnormal  GCT  and  a  single  elevated  
value  on  the  GTT  are  at  increased  risk for  foetal  macrosomia,  neonatal  hypoglycemia  and  
neonatal  hyperbilirubinaemia. 
 
Okun  et  al  showed  that  patients  with  an  abnormal  GCT  and  no  elevated  values  
on  the  GTT  are  at  increased  risk  for  foetal  macrosomia. 
 
Sun  et  al,  in  1995  did  a  prospective  study  on  the relationship  between  50gm.  
GCT  and  pregnancy  outcome.  50gm  OGCT  was performed  on  622  pregnant  women  and  
75gm  OGTT  was  further  done  on  subjects with  screening  test  value of  more  or  equal  to  
7.78mmol/l. 16.56% (103/622)  had  increased  GCT.  Among  whom  32  were  identified  as 
having  GIGT  and  12 ,  GDM by  confirmatory  test  of  75gm  GTT.  Sensitivity  was  42.72% 
(44/103).  The  incidences of  EPH  syndrome,  PROM, foetal macrosomia, operative  deliveries  
and  perinatal  morbidity  were higher in women  with  GIGT/GDM  than  in  women  without  
GIGT/GDM.     It  suggests  that  50gm  GCT  is  ideal  method  of  screening  for  GDM  and  
should  be  performed  on  all  pregnant  women. 
 
Bevier  et  al  studied  103  women  who  had  positive  GCT (>140 mg/dl)  but  a  
negative 100 gm 3 hour OGTT.  The  women  were  randomly  assigned  to  either  experimental  
or  control  groups  with  experimental  receiving  dietary  counselling  and  home  glucose  
monitoring  instruction (HBGM). They  were  reviewed  weekly. All women  had  HbA1C  tests  at       
28  and  32  weeks.  Results  were all women  whom  were  in  dietary  counselling  had  low  
infant  birth  weight,  less  number  of  caesarean  sections  and  low  HbA1C. 
 
Bonomo et al  in  1998 suggested  maintaining  the  140 mg/dl oral      GCT  threshold  
with  diagnostic  target  is  to  recognise  only  women  with  positive  results  of  oral  GTT. To  
prevent  perinatal  risks  in  pregnancies  complicated  by  borderline  glucose  intolerance,  with  
Carpenter  Coustan  criteria  lower  cut-off value (136mg/dl),  could  be  hypothesised  to  improve  
test  sensitivity,  allowing  more  extensive  diagnosis  of  borderline  subjects.  
 
Institute  of  obstetrics  and  gynaecology,  university  of  Florence,  Italy  in  1997  studied  
whether  minor  abnormalities  of  glucose  metabolism  without  gestational  diabetes  are   risk  
factors   for  foetal  over  growth.         A  sample of  1883  unselected  pregnant  women  were  
screened  for  GDM  using  50gm  of glucose, 1 hour  GCT  in  2  periods  of  pregnancy,  early  
(16 – 20weeks)  and  late  (26 -  30 weeks).  Results  were  the  level  of  risk was  related  to  
gestational  age  at the  appearance  of  abnormal  GCT.  Patients  with  an abnormal  GCT  in  
the  early  and late  periods  of  pregnancy  had     a  risk  of  delivering  a  large  for  GA  infant  7  
times  higher  than  the  control  group  (normal  GCT in  both  periods)  and  patients  with  a  
abnormal  GCT  in   the  early  period  and  abnormal  GCT in  the  late  period  showed  a     risk   
3  times  higher  than  the  control  group. 
 
Lao et  al  in  2002  in  Queen  Mary  Hospital,  Hongkong  studied  on  461  LGA  babies,  
the  relationship  between  WHO  category  of  IGT  (2 hr  value  of  75gm  OGTT  at  8 to 
10.9mmol/l)  and  outcome  in  LGA  infants    to determine whether  IGT  affects  perinatal  
morbidity  in  addition  to  affecting  infant  size. IGT group  had  significantly  higher  mean  
maternal  age,  pre-pregnancy  weight  and  BMI, but  no difference in  infant  gestational  age 
and  birth  weight.  However,  IGT  group  had  increased  incidence  of  erb’s  palsy,  meconium  
aspiration  syndrome,  phototherapy,  sepsis  and  shoulder dystocia. 
 
AIM OF STUDY 
   
 To do routine antenatal screening with glucose challenge test    and  to  study the 
incidence of GDM in the study group and positive predictive value of GCT in 
pregnant women attending  antenatal  OP  of  PSGIMS&R  during  a  period   of  
July  2004 – July  2005. 
 
 To study the incidence of GCT positive GTT negative patients             (false  
positive  GCT). 
 
 To  study  the  validity  of  GCT  in  diagnosing  GDM. 
 
 To study the maternal and perinatal outcomes in both GCT  positive  GTT  
negative  patients  and  GDM  patients. 
 
 To compare perinatal outcomes between patients with GCT+ GTT-     patients  and  
patients  with  normal  GCT. 
MATERIALS AND METHODS 
 
A prospective study was carried out in  pregnant  women attending antenatal op in 
PSGIMS&R and all of them were followed till delivery               to   assess   the  maternal  and  
perinatal  outcomes. 
 
SELECTION CRITERIA 
Pregnant  women  attending  antenatal  OPD  were  recruited  for  the  study 
INCLUSION CRITERIA 
 All  pregnant  women  with  gestational  age  between  24 – 28  weeks 
 Any parity  
 Any age 
 Not a known DM 
 
EXCLUSION CRITERIA 
 Gestational  age  of  more  than 28  weeks 
 Known DM 
 Multiple pregnancy 
 Other medical and surgical disorders complicating pregnancy like cushings  disease,  
pancreatitis, hyperthyroidism etc 
 On drugs that would alter glucose and insulin metabolism like corticosteroids,  
thiazides, salbutamol, nifedepine  etc 
 
METHODS 
A  detailed  history  including  the  various  risk  factors  were  taken : 
 Age  
 Ethnicity 
 Obesity 
 Positive  family history of DM 
 Poor reproductive history 
 Previous h/o  prematurity and stillbirth 
 H/o delivery of large infant 
 H/o unexplained  neonatal  death 
 H/o traumatic delivery with associated neurological disorder in the   infant 
 
 H/o congenital anomaly 
 H/o DM  in  the  previous  pregnancy 
 H/o  preeclampsia  in  previous  pregnancy 
 Recurrent severe moniliasis  or UTI 
 Polyhydramnios 
 Glycosuria 
 
O’ Sullivans glucose challenge test 
50 gms of oral glucose mixed with 150 ml of water was given to            all patients without 
regard to the time of the last meal or time of the          day. Glucose given was Dextrose 
Monohydrate D Glucose which is      commercially available. Following the glucose drink, 
patients were            made  to  rest  and  prohibited  from  further eating or drinking except    
water. One hour later 1cc of venous blood  was taken in a dry test tube    and  plasma  glucose  
was  estimated  by  enzymatic  method (glucose oxidase method). Inorder to achieve 
increased sensitivity, according to ACOG 1994 recommendations, a cut-off  value of 130 can 
be taken.         But  conventionally  >140 mgs%  is  considered  as  positive  screening. 
 
3 Hour Oral Glucose Tolerance Test 
 Patients  whose GCT were above 140 mgs% were subjected to 3 hr            oral GTT, 
Since it served as gold standard for diagnosis of GDM.              After taking the fasting sample 
(blood and urine), patients were challenged with 100 gms of glucose. Venous blood was taken 
hourly for a period          of 3hrs along  with collection of urine specimen. The diagnostic criteria      
followed  by  NDDG  is 
  
 
 
 If any two values 
were met or exceeded, a diagnosis of gestational  diabetes was made and if the 2 hour  
plasma glucose was between        115  and  164 mg%, a diagnosis of IGT was made and 
they were   managed  accordingly. All patients were followed up till delivery and          the  
perinatal  outcome  was  analysed. 
 
Fasting 
 
1 hr 
 
2hr 
 
3hr 
 
105 
 
190 
 
165 
 
145mg/dl 
 
5.8 
 
10.6 
 
9.2 
 
8.1mmol/l 
RESULTS   AND   ANALYSIS 
 Total no of antenatal patients screened with GCT        –        500 
 No of patients with positive GCT (>140mg/dl)               –         93 
 No of GCT + patients in whom GTT is positive              _    28 
 Therefore, no. of patients with GCT +GTT-VE                –  65 
 No of patients with negative GCT (>140mg/dl)            –        407 
 
 
 
 
 
 
Ö Positive predictive value of GCT is 30.1% 
Ö Incidence of GDM is 5.6% 
Ö Incidence of  GCT+GTT-VE patients is 13.77%  
GCT -ve
GCT +ve GTT +ve
GCT+ve GTT -ve
ALL  PATIENTS 
SCREENED (500)
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GTT WAS DONE 
GTT –VE (65) 
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GTT+VE (28) 
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TABLE – 1  
AGE GROUP 
 
GCT+GTT-VE (65) GDM (28) AGE NO.OF PTS.(500) 
No % No % 
<20 34 2 5.9 _ _ 
21-30 407 47 11.5 24 5.9 
>31 59 16 27.1 4 6.8 
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TABLE-2 
GRAVIDITY 
GCT+GTT-(65) 
GDM 
(28) Gravida 
No of pts 
(500) 
No % No % 
1 227 23 10.1 10 4.4 
2 178 22 12.4 12 6.7 
3 68 19 27.9 3 4.4 
4 19 1 5.3 3 15.8 
5 8 _ _ _ _ 
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GCT+GTT-VE(65) GDM( 28) 
SES 
NO OF PTS 
(500) No % N0 % 
I _ _ _ _ _ 
II 18 3 16.7 2 11.1 
III 71 24 33.8 11 15.5 
IV 353 30 8.5 13 3.9 
V 58 8 13.8 2 3.4 
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GCT+GTT-VE (65) GDM (28) 
BMI 
NO OF PTS 
(500) No % No % 
<20 6 1 16.7 _ _ 
21 – 25 181 19 10.5 5 2.8 
26 -30 244 33 13.5 12 4.9 
>31 69 12 17.4 11 15.9 
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TABLE – 5 
FAMILY H/O DIABETES 
 
GCT+GTT-VE(65) GDM (28) FAMILY  H/O 
DM 
NO OF PTS 
(500) 
No % No % 
FATHER 28 9 32.1 4 14.3 
MOTHER 18 4 22.2 4 22.2 
BOTH 3 1 33.3 1 33.3 
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TABLE – 6 
POSITIVE URINE SUGAR 
 
GCT+GTT- (65) GDM (28) URINE 
SUGAR 
TOTAL NO 
OF PTS(500) No % No % 
POSITIVE 7 2 28.6 3 42.9 
   
 
PRESENT OBSTETRIC HISTORY 
Total no of AN women screened – 500 
 
PREECLAMPSIA 
Ö Total no of women with PIH -36 
(mild – 33;severe -3) 
Ö NO of women with group I with PIH – 8 
(mild -7;severe -1) 
 
GCT+GTT-VE(65) GDM(28) PRESENT 
OBSTETRIC 
HISTORY 
TOTAL NO OF 
PATIENTS(500) 
No % NO % 
 
PREECLAMPSIA 36 8 12.3 2 7.1 
 
HYDRAMNIOS 
 
GCT+GTT-VE(65) GDM(28) PRESENT 
OBSTETRIC 
HISTORY 
TOTAL NO OF 
PATIENTS(500) 
No % NO % 
 
HYDRAMNIOS 7 2 3.1 2 7.1 
 
 
PRETERM DELIVERY 
 
GCT+GTT-VE(65) GDM(28) PRESENT 
OBSTETRIC 
HISTORY 
TOTAL NO OF 
PATIENTS(500) 
No % NO % 
PRETERM 
LABOUR 
28 2 3.1 1 3.6 
 
 
H/O PREVIOUS LSCS 
 
 Total no of cases – 59 
 GCT +GTT- cases with previous lscs - 8 
 GDM with previous lscs – 3 
PREVIOUS OBSTETRIC HISTORY 
 
          In GCT + GCT –VE : 
 Previous 2 neonatal deaths (1 due to severe PIH) 
 Previous anencephaly – 2 
 Previous hydrocephalus - 1 
 Anomaly – 1 (diaphraghmatic hernia) 
 
          In GDM : 
 Previous neonatal deaths – 2 
 Previous IUD – 2 (1 was due to severe PIH) 
 H/O GDM in previous pregnancy – 1 
 H/O  previous macrosomia – 1 (4.2 kgs) 
 
 TABLE - 7 
GESTATIONAL AGE 
 
GCT+GTT-(65) GDM (28) GESTATIONAL 
AGE 
TOTAL NO OF 
PTS(500) 
No % NO % 
TERM 472 63 13.3 27 5.7 
PRETERM 28 2 7.1 1 3.6 
 
 
TABLE -8 
MANAGEMENT 
 
TREATMENT NO OF GDM % 
MEALPLAN 20 71.4 
INSULIN 8 28.6 
 
 
TABLE – 9 
ONSET OF LABOUR 
 
GCT+  GTT-VE (48) GDM  (15) 
ONSET OF LABOUR 
No % NO % 
SPONTANEOUS 30 62.5 5 33.3 
INDUCED 18 37.5 10 66.7 
 
Out of those delivered vaginally, 62.5%  had spontaneous onset and        37.5% had induced 
labour in group I and 33.3% had spontaneous onset      and  66.7%  had  induced  labour  in  
group  II. 
010
20
30
N
O
 O
F 
C
A
SE
S
LA
B
O
U
R
N
A
TU
R
A
L
VA
C
U
U
M
FO
R
C
E
P
S
E
LE
C
TI
V
E
 C
/S
E
M
E
R
G
E
N
C
Y
C
/S
MODE OF DELIVERY
GCT+ GTT-
GDM
TABLE – 10 
 MODE OF DELIVERY 
 
 
 
 
 
 
 
 
GCT+ GTT-(65) 
GDM(28) 
MODE OF DELIVERY 
No % No % 
LABOUR NATURAL 30 46.2 10 31.7 
 
VACUUM 18 27.7 4 14.3 
 
FORCEPS _ _ 1 3.6 
 
ELECTIVE C/S 7 10.8 3 10.7 
 
EMERGENCY C/S 10 15.4 10 35.7 
INDICATIONS FOR CAESEREAN SECTION 
GROUP I : 
ELECTIVE: 
 Previous lscs with hydramnios    –  1 
 Previous lscs with CPD major    –  3  
 Previous lscs with BOH      –  1  
 Oligohydramnios with vulval warts   –  1  
 CPD major and macrosomia    –  1 
 
EMERGENCY: 
 Non progression of labour   –  6 
 Fetal distress     –  2 
 Severe PIH with IUGR with fetal distress  –  1 
 Breech      –  1 
 
IN GROUP II: 
ELECTIVE LSCS: 
 Previous lscs with CPD     –  1 
 BOH      –  1  
 CPD major with macrosomia    –  1 
 
EMERGENCY LSCS: 
 Nonprogression of labour    –  5 
 Fetal distress      –  4 
 Oligo hydramnios and fetal distress   –  1 
 
MATERNAL MORTALITY AND MORBIDITY – NIL 
 
PERINATAL MORTALITY – NIL 
 
PERINATAL MORBIDITY: 
TABLE – 11 
BIRTH WEIGHT 
 
 
GCT+GTT-VE 
 
GDM 
BIRTH WEIGHT 
 
 
 No % No % 
<2 1 1.5 1 3.6 
2 – 2.5 2 3.1 3 10.7 
2.6 – 3 27 41.5 8 28.6 
3.1 - 3.5 29 44.6 10 35.7 
3.6 – 4 5 7.7 5 17.9 
>4 1 1.5 1 3.6 
Ö Mean birth weight in group I – 3.09 
Ö Mean birth weight in GCT –VE – 2.94 
Ö Mean birth weight in group II – 3.01 
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TABLE – 12  
APGAR 
 
GCT+GTT-VE GDM 
APGAR 
No % NO % 
<6/10 2 3 _ _ 
>7/10 63 97 28 100 
5MT APGAR <6/10 _  _ _ 
PERINATAL OUTCOMES 
NICU ADMISSION:  
 
Ö In group I, 31 (47.7%)babies got admitted to NICU. 
Ö In the group II,19(67.9%) babies got admitted in NICU. 
Ö In the control group,101 (24.8%) babies got admitted in NICU. 
 
 
NICU ADMISSION 
GCT–VE 
CASES(407) 
GCT+GTT-VE 
(65) 
GDM(28) 
Hyperbilirubinaemia 74 21 15 
RDS 19 8 5 
TTN 13 5 1 
Hypoglycaemia 3 8 5 
Meconium Aspiration 
Syndrome 
3 ----- ---- 
Birth asphyxia 12(1-severe) 2 1 
IUGR 5 ----  
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MACROSOMIA 
Ö In group I – 1.6% of babies had macrosomia 
Ö In group II – 3.6% of babies  had macrosomia 
Ö In GCT – VE group, 0.5% of  babies had macrosomia 
 
 
SHOULDER DYSTOCIA 
Ö In group I – 1.6% 
Ö In group II  – 3.6% 
Ö In GCT –VE – 0.25% 
 
ERB’S PALSY 
In group I, 2 babies had erb’s palsy compared to none in group II and         normal  GCT  group. 
 
ANTENATAL DEATH 
No antenatal deaths in both group I and group II groups compared to 3 in    normal  GCT group. 
 
 
COMPARING  THE  DEMOGRAPHIC AND PERINATAL OUTCOMES  
BETWEEN  GCT+ GTT-VE  AND  GCT –VE  GROUP 
 
DEMOGRAPHIC 
PARAMETERS 
 
 
GCT+GTT-VE 
 
GCT -VE 
 
t 
 
P 
MEAN  AGE 27.2 25.6 3.15 0.01(SIGNIFICANT) 
MEAN  BMI 26.55 25.77 1.711 0.1(NOT 
SIGNIFICANT) 
MEAN BIRTH 
WEIGHT 
3.09 2.94 0.68 0.5(NOT 
SIGNIFICANT) 
 
PERINATAL 
OUTCOME 
GCT+GTT-VE
(65) 
GCT-VE 
(407) 
ODDS 
RATIO 
 
P 
NICU ADMISSION 31 (47.7%) 101(24.8%) 2.76 
(1.56 – 
4.88) 
<0.001(SIGNIFICANT) 
MACROSOMIA 1(1.6%) 2(0.5%) 2.44 
(0.49 – 
12.3) 
0.88 (NOT SIGNIFICANT) 
SHOULDER 
DYSTOCIA 
1(1.6%) 1(0.25%) 3.67 (0.9 
– 14.9) 
0.64 (NOT SIGNIFICANT) 
ERB’S PALSY 2(3.2%) 0 7.46 (5.9 
– 9.39) 
0.018(SIGNIFICANT) 
C/S 17(35.4%) 111(37.5%) 0.94 (0.5 
– 1.77) 
0.85(NOT SIGNIFICANT) 
PREECLAMPSIA 8(12.3%) 26(6.38%) 2.06 (0.8 
– 5.1) 
0.07(NOT SIGNIFICANT) 
From this study, it shows that higher the maternal age, more chances   of developing 
glucose intolerance. Mean maternal age rates, NICU    admission and erb’s palsy rates are 
statistically significant (P<0.05) in GCT+GTT-VE  group  when  compared  to  normal  GCT-VE  
group. 
 
GCT VALUES BETWEEN 130 – 140 
No of patients with GCT values between 130–140 mg/dl–24. 4 babies born to these 
mothers were admitted in NICU, 2 had hyperbilirubinaemia,        1 had hypoglycaemia and 1 had 
IUGR. Comparing this group with GCT <130mg/dl,  odd’s  ratio  is 0.59 (0.17–1.89). P=0.34 
(>0.05% - not significant). 
 
VALIDITY OF O’SULLIVANS GLUCOSE CHALLENGE TEST 
500 unselected pregnant women were subjected to O’Sullivan glucose challenge test. 93 
(18.6%) had values above 140 mgs%, among them 28 (30.1%) had GTT+ with O’Sullivan & 
Mahan GTT. 
 
OGCT + OGCT GDM 
>140MGS/DL 93 (18.6%) 28 (30.1%) 
 
CARLOTITI N et al conducted a mass screening for gdm using O’SULLIVAN GCT test in 
751 women with 28 weeks of gestation. GCT positive  in 18% of cases. Oral GTT confirmed the 
diagnosis in 14% of GCT positive cases. Compared with our study, where O’Sullivan GCT test 
was positive in 18.6%,  oral  GTT confirmed  the diagnosis in 30.1% of  these  positive  patients. 
DISCUSSION 
Gestational Diabetes Mellitus is one of the commonest medical complications of 
pregnancy. GDM is a risk factor for both mother and foetus. The risk increases proportionally to 
the to the maternal blood sugar concentration. So we have to screen all antenatal patients with 
glucose challenge test  between 24 – 28 weeks of gestation and proceed with GTT if GCT is  
positive. Early  diagnosis  of GDM  reduces  perinatal  morbidity  and  mortality. 
 
In this study, incidence of GDM is 5.6% Incidence of GCT+GTT–VE patients was 
13.77%. STAMILIO et al (2004) studied 1825 eligible pregnant women among a cohort of 1998 
patients and identified 164 patients              with GCT+GTT-VE and 50 patients with  GDM, where  
the incidence of  GCT+GTT-VE was 9.23%. MOSES et al (1995) performed  GTT in 1185 women 
and found that GDM was present in 6.7% of women. GDM was  present  in  8.5 %  of  women  
aged  more  than 30 yrs. 
 
In our study positive predictive value of GCT was 30.1%.           JIMENEZ – MOLCON  et  
al  reported  that, GCT has a  positive  predictive  value  of  12– 40% 
 
In this study false +ve GCT was present  in 5.9%  of women aged <20yrs,  11.5%  of 
women  aged  21-30 yrs,  27.1% of women aged >31yrs. 
GDM  was present  in 5.9% of women aged  21-30 yrs and 6.8%           of women >31yrs. 
Most patients in both groups belonged to the age          group  21–30 years and some patients 
were in the age group above 30      years showing  that  increase  in  age  could  lead  to  GDM  
and  glucose  intolerance. 
 
In this study, mean age in GCT+GTT-VE group is 27.2 and in          normal GCT–VE 
group is 25.6, which is statistically significant (P<0.01).          In the study conducted by 
STAMILIO et al, mean age in GCT + GTT –ve  group was 28.5 and in normal GCT –VE group 
was 25.5, which was statistically  significant  (P – 0.001) 
 
In our study, GCT+ GTT-VE was present in 10.1% of primi, 12.4%         of second  
gravida, 27.9% of third gravida and 5.3% of fourth gravida.        GDM  was  present in 4.4% of 
primi, 6.7% of second gravida, 4.4% of third  gravida  and  15.8%  of  fourth  gravida.   In our 
study, in both groups, more % of women were found in third gravida. This shows that the more 
the number    of   pregnancies,  the  occurrence  of  glucose  intolerance  increases. 
 
In our study, in GCT + GTT –VE group, 16.7%  belong to II SES,  33.8 %  to III SES, 
8.5%  to IV  SES ,13.8 %   to  V  SES.  In GDM , 11.1%  belong to SES II ,15.5%  to SES III , 
3.9%   to  SES IV ,3.4%   to  SES V.  In both groups, more  %  of  women  belong  to  higher  
socioeconomic  strata. 
In this study, GCT+GTT–VE  results were present in 16.7 % of women with BMI < 20, 
10.5% of women with BMI of 21–25, 13.5%  of women with   BMI  of 26 – 30, 17.4 % of women 
with BMI >30.  GDM was present in 2.8%   of women with BMI 20 – 25, 4.9% of women with BMI 
26 – 30,15.9% of  women with  BMI >30. 
 
In our study, more no of women were found with BMI above 26   showing that glucose 
intolerance and BMI are directly proportional to          each other. In our study, mean BMI in 
GCT+GTT-VE is 26.55 and in        normal  GCT –VE  is  25.77, which  is  not  statistically  
significant  (P – 0.1). 
 
In the study conducted by STAMILIO et al, mean BMI WAS 28.5           in GCT+GTT-VE 
group and 25.5 in normal GCT–VE group, which was significant  (P<0.001). 
 
In this study, in GCT+VE GTT–ve group, 32.1% had family h/o DM       in father, 22.2% 
had family h/o DM in the mother and 33.3% in both       parents.  In GDM, 14.3%  had DM  in  the  
father, 22.2% in  the  mother,   33.3%   in  both   the  parents. 
 
MOSES et al showed that GDM was present in 11.6% with positive    family history.  
According to GARNER el al (1995) if mother had IDDM,            1–3% of offsprings developed 
diabetes, if father had IDDM, 6% developed diabetes  and with positive H/O DM in both parents 
20% developed     diabetes. Hence  a  H/o IDDM in the father is of greater predictive value than  
in the mother and  even greater when a sibling is diabetic. A family history       in grand parents is 
less significant. Family H/O diabetes either in the first degree or in the second degree relative is 
an important risk factor for developing abnormal glucose tolerance (5 – 10  times  risk  greater  
than  for  children with non diabetic parents).  
 
In  this  study, urine sugar was positive in 7 patients out of 500. In the GCT+GTT-group, 
28.6% had positive urine sugar. In GDM, 42.9% had      positive  urine  sugar. 
 
Urine sugar is not a sensitive test for identifying patients with glucose intolerance. Most 
pregnant patients have renal glycosuria as a result of         low threshold  for  elimination  of  
glucose by the kidneys and  have normal kidneys.  
 
In  this  study, % of PIH in GCT+ GTT- is 12.3% and % of GDM and       PIH -7.1%. 
According to STAMILIO et al (2004), 6.5% of patients with        GCT+ GTT- had PIH.  According 
to GABBE et al (1997) and JACOBSON  & COUSIN (1989),the rate of PIH among GDM subjects 
is not significantly    different from controls. GARNER et al & ROSSEN et al have shown that       
PIH  was  twice  high  in  GDM. 
 
In  this  study, % of  hydramnios in  women  with GCT+GTT-VE – 3.1% and % of 
hydramnios in patients with GDM -7.1%. JACOBSON & COUSIN     et al reported an incidence of 
hydramnios in GDM patients as 2%       compared with our study where incidence was 3.1% in 
GCT+GTT- patients  and 7.1% in GDM. Hydramnios affects approximately 0.4% 1.5 % of all 
pregnancies. Diabetes mellitus may be responsible for approximately 14%      of all cases of 
polyhydramnios.  In our study, the incidence of hydramnios       is  only 7.1% in GDM, showing  
that  the  diabetic  status  during  pregnancy  was  well  controlled. 
 
In GCT + GTT-VE cases, preterm labour occurred in 2(3.1%) and in   GDM,  preterm  
labour  occurred in 1(3.6%).  Incidence of preterm labour in GDM as per 1986 – 1993 review was 
7.3% and 20 – 40% in overt diabetes compared with our study where incidence of preterm labour 
in GCT+GTT- cases were 3.1% and in GDM, it is 3.6%. the incidence of preterm labour        is 
more in overt  DM than in GDM and GCT+GTT- because of increased      risks  of  infections  like  
chorioamnionitis  precipitating  preterm  labour. 
 
In GCT + GTT –VE, there were previous history of 2 neonatal deaths        (1 due to 
severe PIH), 2 anencephaly, 1 hydrocephalus and 1 anomalous  baby (diaphraghmatic hernia). In 
all these patients, probably GDM was missed in previous pregnancy. In GDM, there were 
previous history of 2 neonatal deaths, 2 IUD (1 was due to severe PIH), 1 patient had H/O GDM 
in     previous  pregnancy  and  macrosomia – 1 (4.2 kgs) 
 
In our study,13.3% and 7.1% delivered at term and preterm   respectively  in GCT+GTT-
VE group and 5.7% and 3.6% delivered at term    and  preterm  respectively.  
 
20 out of 28 (71.4%) were treated with mealplan till delivery. 8 out          of 28 (28.6%) 
were switched from mealplan to insulin due to poor glycemic control, till delivery. According to 
ACOG technical bulletin, 10 – 15% of  patients  with  GDM  require  insulin. 
 
In our study, in GCT+GTT-VE group, 46.2% delivered normally,     27.7% delivered by 
vacuum, 10.8% by elective LSCS and 15.4% by emergency  LSCS  being  done  for  macrosomia  
in 1.5%. In GDM group, 35.7% delivered normally, 14.3% delivered by vacuum, 3.6% by forceps, 
10.7% by elective LSCS, 35.7% delivered by emergency  LSCS  being        done for macrosomia 
in 3.6%. COUSTAN and EMARAH et al (1994) in a retrospective study of 299 cases found that 
caeserean section  was  done        in  44.4%  of  cases,  being  done  for  macrosomia  in  7%  of  
cases.  
 
Eventhough LSCS rate is high in GCT+GTT-VE group, it is not  statistically significant 
(P=0.85) when compared to normal GCT group,         where  the  LSCS  rate  was  37.5%  
because  of  increased  previous  LSCS rates. 
 
In the immediate postpartum period, once the patients resumed     normal diet, fasting 
and postprandial blood sugar was checked in GDM.       Out  of  28, 3  had  elevated   FBS  and  
PPBS  (10.7%). 
 
Mean  birth weight in GCT+GTT –VE  patients – 3.09, mean birth weight   in GCT –VE 
patients – 2.94 and mean birth weight in GDM – 3.01. There were about  41.5% of babies 
weighing between 2.6 – 3 kgs, 44.6% of babies   weighing between 3.1–3.5 kgs, 7.7% of babies 
between 3.6–4 kgs, 1.5%         >4 kgs, 1.5% was <2kgs and 3.1%  were  between 2 – 2.5 kgs in 
GCT+GTT-VE group. 
 
In the GDM group, 28.6% of babies weighed between 2.6 – 3 kgs, 35.7%        of babies weighed 
between 3.1 - 3.5 kgs, 17.9% were between 3.6 – 4 kgs   and 3.6% were > 4 , 3.6%  were less 
than 2 kgs and 10.7% were between       2 -2.5 kgs. 
 
In the STAMILIO et al (2004) study, mean birthweight is 3.304 kgs         in GCT+GTT- 
patients and 3.194 kgs in normal GCT patients.  Because of          the treatment given to GDM, 
incidence of macrosomia is very less in our    study group. In our study, when comparing mean 
birth weight between GCT+GTT-VE  and  normal  GTT group,  it is not statistically significant 
(P=0.5).  
 
In our study, in GCT +GTT-VE group, 1 mt apgar  was >7/10 in 63 (97%)  of  babies and 
2(3%) babies had apgar <6/10. In these babies 5 mt apgar   was  above 7/10. In GDM  group, all  
babies  had  apgar >7/10. 
 
All  babies in GDM group had good apgar because of good glucose control  and  prompt  
resuscitation. 
 
Maternal mortality was nil. 
Perinatal  and  neonatal  mortality  was  nil 
 
 In  GCT +GTT-VE group, 47.7% babies got admitted to NICU. In the GDM group, 
67.85% babies got admitted in NICU. In the control group,    24.8% babies got admitted in NICU. 
Factors taken into account for            NICU admission were hyperbilirubinaemia, hypoglycaemia, 
respiratory   distress syndrome, meconium aspiration syndrome, transient tachypnoea       of 
newborn, birth asphyxia and IUGR. When comparing GCT+GTT-VE      group and control group, 
NICU admission is statistically significant in GCT+GTT-VE (P <0.001). 
 
In the study by STAMILIO et al,14 babies (8.6%) got admitted to    NICU. In the normal 
GCT group, 163 babies (9.8%) got admitted (statistically not significant, P – 0.61).  
 
REY et al reported that patients with an abnormal GCT  and a single elevated value on 
the GTT are at increased risk for fetal macrosomia,   neonatal  hypoglycaemia  and   neonatal  
hyperbilirubinaemia. 
 
KHAN et al reported that patients with a positive glucose screening    test and a negative 
GTT were at increased risk for fetal macrosomia, caeserean delivery  and  pre-eclampsia.  
 
In GCT+GTT–VE group, 1.6% baby had macrosomia,in GDM, 3.6% baby had 
macrosomia, in GCT–VE group, 0.5% babies had macrosomia, (statistically not significant, P-
0.88). In the STAMILIO et al study, 14 babies (8.5%) had macrosomia in the GCT+GTT- and 95 
babies (5.7%) in the    normal  GCT group,  (statistically  not  significant,  P – 0.15). 
 
Using a case control study design, OKUN et al showed that         patients with an 
abnormal GCT and no elevated values on the GTT are at increased risk  for  foetal  macrosomia.  
The  incidence  of  macrosomia  is  less  in  GDM  because  of  good  glycaemic  control  in  
pregnancy. 
 
In GCT+GTT-VE group, 1.6% baby had shoulder dystocia, in GDM, 3.6% baby had 
shoulder dystocia and in GCT –VE, 0.25% baby had     shoulder  dystocia. When  comparing  
these  two  groups  it  is  not  statistically  significant (P= 0.64). 
 
In the study by STAMILIO et al, shoulder dystocia was present in 8 babies (4.9%)  in GCT +GTT-
VE group  and in 29 babies (1.7%) in normal GCT  group,  statistically  significant  (P=0.007). 
 
In GCT+GTT-VE group,2 babies had erb’s palsy compared to           none   in  GDM  and  
normal  GCT  group  (statistically  significant,  P.018). 
 
35.4% babies delivered by C/S in GCT +GTT-VE group compared        to 37.5% in 
normal GCT group.  46.4% babies delivered by C/S in GDM.          In the study by STAMILIO et 
al, 18 babies (23.8%) were delivered by caeserean section in GCT +GTT-VE group and 286 
babies (17.2%) were delivered  by  caeserean  section  in  normal  GCT  group. 
 
No antenatal deaths in both GCT=GTT-VE and GDM groups    compared   to 3 in normal 
GCT group. In the study by STAMILIO et al,        there were 1.2% antenatal  death  in  
GCT+GTT-VE  group  and 6 (0.4%)       in  normal  GCT  group. 
 
From this study, it shows that higher the maternal age, more chances   of developing 
glucose intolerance. Mean maternal age rates, NICU     admission and erb’s palsy rates are 
statistically significant(P<0.05) in GCT+GTT-VE   group  when  compared  to  normal  GCT-VE  
group. 
 
In the study by STAMILIO et al, mean BMI, mean maternal weight, mean birth weight 
rates were statistically significant (P<0.05) in GCT+       GTT-VE group when compared to normal 
GCT group. Shoulder dystocia     and caeserean delivery are significant in GCT+GTT-VE group 
when   compared  to  normal  GCT  group. 
 
No of patients with GCT values between 130 – 140 mg/dl were  24.       4 babies born to 
these mothers were admitted in NICU,2 had hyperbilirubinaemia, 1 had hypoglycaemia and 1 had 
IUGR. Comparing this group with GCT <130mg/dl, odd’s ratio is 0.59 (0.17–1.89). P=0.34       
(>0.05% -not significant).  So according  to  this  study, we  need  not  subject  patients  with  
GCT <140  mgs/dl  to GTT. 
 
500 unselected pregnant women were subjected to O’Sullivan     glucose challenge test. 
93 (18.6%) had values above 140 mgs%, among   them  28  (30.1%)  had  GTT+ with  O’ Sullivan  
&  Mahan GTT. 
 
CARLOTITI N et al conducted a mass screening for GDM using O’Sullivan GCT test in 
751 women with 28 weeks of gestation. GCT positive   in 18% of cases. Oral GTT confirmed the 
diagnosis in 14% of GCT         positive cases. Compared with our study, where O’Sullivan GCT 
test was positive  in  18.6%, oral  GTT  confirmed  the  diagnosis in  30.1%  of  these  positive  
patients. 
 
                                                    
CONCLUSION 
 
Of 500 patients taken up for the study, incidence of GDM in our       study  is 5.6%. 
Incidence of GCT+GTT–VE patients was 13.77%. OGTT is    the gold standard in the diagnosis 
of abnormal glucose tolerance during pregnancy and perhaps is desirable even as a screening 
test. Owing to practical difficulties, O’Sullivan  glucose challenge test is a convenient, economical 
and suitable alternative screening test without sacrificing  sensitivity  expected  of  a  screening  
test. Positive  predictive  value  of  GCT  in  our  study  was  30.1%. 
 
False positive GCT (GCT+GTT-VE) is identified as an independent       risk factor for 
adverse perinatal outcome, including the maternal outcome variable, NICU admission, shoulder 
dystocia, foetal macrosomia, caesarean delivery and antenatal death. So identifying these 
patients is important,             so  that we can monitor them well and can prevent complications.               
They could benefit from additional therapies, such as more intensive         foetal  monitoring,  
nutritional  counselling  or  a  diabetic diet. 
 
From this study, it shows that higher the maternal age, more chances      of developing 
glucose intolerance. Mean maternal age rates, NICU     admission and  erb’s palsy rates are 
significant (P<0.05) in GCT+GTT-VE group   when  compared  to  normal GCT-VE  group. 
 
If  the  GCT <140 mg/dl,  they  can  be  treated  as  normal. 
 
In the case of macrosomia occuring in the normal GCT group,      patients    are  advised  
to do  postnatal fasting and postprandial blood sugar. 
 
As per the recommendations of the international workshop conference of  gestational 
diabetes, all pregnant women should be screened for gestational diabetes at 24–28 weeks of 
gestation by  O’ Sullivan's 50 gms glucose challenge test. It  is important for two reasons. First,  
identification      of women with GDM followed by appropriate treatment and monitoring          will  
reduce  foetal macrosomia and  identify those women at risk  for foetal macrosomia. Second, 
given the high likelihood that women who manifest  GDM will develop type II. Identification of 
these patients will permit   intervention  after  delivery   that  might delay  or  prevent  the  onset  
of  type -II Diabetes Mellitus. 
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PROFORMA 
ROUTINE ANTENATAL SCREENING WITH GLUCOSE 
CHALLENGE TEST 
AND ITS RELATION WITH PERINATAL OUTCOME 
Name  : 
Age  : 
SES  : 
Education : 
Gravida :  Para :   Livebirth:  
 Abortions: 
LMP  : 
EDD  : 
Menstrual History: 
Obstetric History: 
 
Past History : 
Family History: 
Examination: 
Date Height Weight B.P Pedal 
edema 
P/A Expected 
uterus 
size 
       
       
       
       
       
       
       
       
       
 
Investigations: 
Urine sugar  : 
GCT   : 
GTT   : 
USG            :  
HbA1C  : 
(in mother with poor 
perinatal outcome) 
 
In GTT +ve, periodical blood sugar F & PP : 
 
 
 
Treatment:   Diet   /  insulin   /  OHA 
 
 
If on Insulin drug dose : 
 
 
GA at time of delivery : 
 
 
Mode of delivery  : (1) Vaginal      (2) Elective LSCS (3) 
Emergency LSCS 
 
If vaginal:     Spontaneous        /   induced 
 
If induced:   Mode of induction 
 
I stage of labour: 
 
 
 
II stage of labour: 
 
 
 
III stage of labour: 
 
 
 
Baby :   Liveborn    /  Deadborn 
 
If live born   APGAR: 
    Weight: 
    NICU admission: 
 
 
 
If deadborn   Fresh death 
    Macerated 
 
 
Maternal complications: 
 
 
 
Postnatal blood sugar in GDM: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
No. Name Age SES Obst. 
Score 
GA Obs. 
History 
Risks Fam
Hist
ory 
BMI PN 
Bld. 
Sugar 
Urine 
Sugar 
GCT GTT Periodi 
Cal  Bld. 
Sugar 
Diet
Insul
01. Shanthi 29 II G3P1L4A1 T Pr CS - - 26.04 - - 163 N - - 
02. Vanitha 27 IV Primi T - - - 27.43 - - 142 N - - 
03. Shabita 27 III G3P2L4 T Anen. - - 30.42 - - 147 N - - 
04. Nirmala 20 IV G2A1 T - - F 27.12 - - 140 N - - 
05. Mahes 22 III G2A1 T - GDM F 26.08 N - 153 GDM N D
06. Padma 21 IV Primi T -  - 26.06 - - 108 - - - 
07. Sumathi 22 IV P T - PIH - 30.89 - - 80 - - - 
08. Jeeja 30 III G2P1L4 T -  - 26.29 - - 112 - - - 
09. Amuda 32 III G3P1L4A1 T Pr CS Oligo - 33.33 - - 100 - - - 
10. Lakhmi 26 IV Primi PT - PIH  - 29.51 - - 125 - - - 
11. Chitra 27 IV G2P1L0 T Pr SB - - 27.92 - - 107 - - - 
12. Jaya 27 IV G3P1L4A1 T - - - 25.75 - - 108 - - - 
13. Shanthi 20 III Primi T - - F 24.55 - - 134 - - - 
14. Sathya 28 III Primi T - - - 31.84 - - 116 - - - 
15. Vincy 24 IV G3P2L2 T - - - 25.28 - - 106 - - - 
16. Vijaya 22 IV Primi PT - - F 20.17 - - 118 - - - 
17. Deivani 23 V G2P1L0 T Pr CS - - 23.11 - - 110 - - - 
18. Mahes 29 IV G3P1L1A1 T Pr CS - - 27.02 - - 108 - - - 
19. Akila 28 III Primi T - - - 26.07 - - 88 - - - 
20. Indira 28 IV G4P2L1A1 T Pr CS - - 26.20 - - 136 - - - 
21. Devika 23 IV G4P2L1A1 T - - - 41.53 - - 134 - - - 
22. Chitra 30 III G2P1L1 T - - - 24.06 - - 116 - - - 
23. Kala 24 IV G4P1L4A2 T - - - 26.05 - - 120 - - - 
24. Gandhi 23 IV Primi T - - - 21.41 - - 77 - - - 
25. Bagya 23 IV Primi T - - - 26.11 - - 112 - - - 
26. Saranya 29 IV G2P1L1 T Pr  
CS 
- - 27.12 - - 116 - - - 
27. Sasi 20 IV Primi T Oligo. - - 25.67 - - 77 - - - 
28. Prema 21 V P T - PIH - 22.08 - - 80 - - - 
29. Bagyla 26 III G2P1L1 T Pr CS - - 23.62 - - 100 - - - 
30. Sudha 26 III G4P2L1A1 T Pr CS - - 26.29 - - 101 - - - 
31. Rajmani 27 IV Primi T Pr CS - - 21.05 - - 103 - - - 
32. Revathy 21 V Primi T - - - 20.95 - - 63 - - - 
33. Carolin 27 IV G2P1L1 T - PROM - 25.56 - - 81 - - - 
34. Shantha 38 IV G2P1L1 T - PIH M 25.63 - - 141 N - - 
35. Anurda  26 III G2P1L1 T - - - 24.38 - - 132 - - - 
36. Rabiya 23 IV Primi T - - - 27.12 - - 116 - - - 
37. Lavana 26 III Primi T - - - 22.65 - - 118 - - - 
38. Sabitha 23 III G3P1L1A1 T - - - 24.03 - - 134 - - - 
39. Sunitha 23 III Primi T - Oligo - 24.52 - - 83 - - - 
40. Priya 22 III Primi T PROM - - 18.55 - - 90 - - - 
41. Kiritika 26 IV Primi T - - - 26.28 - - 130 - - - 
42. Sulo 27 III G2P1L1 T - - F 29.23 - - 146 N - - 
43. Rani 23 III Primi T - - - 27.12 - - 124 - - - 
44. Subha 25 IV G3A2 T - - - 31.24 - - 69 - - - 
45. Vasatha 28 IV G2P1L1A1 T Pr CS - M 28.57 - - 90 - - - 
46. Kavitha 30 III G2P1L1 T - - - 24.88 - - 112 - - - 
47. Gowsal 26 IV Primi T - - - 21.11 - -- 69 - - - 
48. Kavitha 25 IV Primi PT - HIV+ - 22.31 - - 90 - - - 
49. Rani 30 IV G2P1L1A1 T - - - 24.45 - - 101 - - - 
50. Kumua 25 III G2P1L1 T Pr CS - - 20.77 - - 112 - - - 
51. Naga 30 IV Primi T - - - 19.90 - - 108 - - - 
52. Patmal 27 III Primi T - - - 25.14 - - 118 - - - 
53. Neela 30 IV G2P1L1 T - - - 24.09 - - 120 - - - 
54. Mena 20 III Primi T - - - 24.34 - - 79 - - - 
55. Parvaty 25 IV Primi T - PROM - 27.43 - - 89 - - - 
56. Karuna 34 IV G2P1L1A1 T - - - 24.53 - - 112 - - - 
57. Kala 24 IV G2P1L1 T - - - 23.62 - - 108 - - - 
58. Malar 25 V G6P2L2A3 PT - - - 17.62 - - 95 - - - 
59. Sahar 28 V Primi PT - Oligo - 18.90 - - 100 - - - 
60. Shantha 23 IV G2P1L1 T - - - 21.87 - - 119 - - - 
61. Shanthi 28 IV G2P1L1 T - VVB - 23.92 - - 72 - - - 
62. Chitra 26 III P T - - MF 25.76 - - 140 - - - 
63. Malathy 23 III P T - - - 25.28 - - 142 - - - 
64. Mallika 32 IV P T - - M 26.47 - + 162 N - - 
65. Anita 19 III P T - - - 25.63 - - 181 - - - 
66. Chitra 23 III P T - - - 23.93 - - 140 - - - 
67. Parvaty 23 III P T - Epilep - 27.76 - - 153 - - - 
68. Dowlath 28 V P T - GDM - 30.26 - - 145 N D N
69. Rajesh 22 IV P T - GDM - 22.22 - - 150 N D N
70. Sugnya 22 III P T - GDM M 32.79 - - 146 N D N
71. Baby 28 IV P T - Rh  - 27.30 - - 123 - - - 
72. Sujatha 30 IV G2P1L1 T - GDM - 35.6 - - 114 - - - 
73. Jeyama 27 IV Primi T - Oligo - 25.96 - - 122 - - - 
74. Malathy 27 III P PT - Oligo - 25.47 - - 100 - - - 
75. Vanitha 25 III G2P1L1 T - TMS - 31.93 - - 92 - - - 
76. Sunitha 28 III P T - TMS F 27.88 - - 117 - - - 
77. Vijaya 22 IV G2P1L1 T Pr CS Polio - 20.92 - - 83 - - - 
78. Adhi 34 IV G2P1L1 T Pr CS Oligo - 24.12 - - 86 - - - 
79. Amsa 25 IV Primi T - - F 26.10 - - 98 - - - 
80. Selvi 25 IV G2P1L1 T Pr CS - - 26.63 - - 101 - - - 
81. Karpam 31 III G3P1L1A1 T Pr CS - - 31.93 - - 140 N - - 
82. Vimala 28 V G2P1L1 T Pr CS - - 19.94 - 118 - - - - 
83. Saras 33 III G3P1L1A1 T Rh - - - 26.02 - 136 - - - - 
84. Mohana 25 II Primi T Oligo - - 19.47 - 111 - - - - 
85. Maha 33 V G2P1L1A1 T Pr CS - - 34.01 - 114 - - - - 
86. Rani 23 IV G3P1L1A1 T Pr CS - - 27.63 - 103 - - - - 
87. Kavitha 34 III Primi T - - - 37.09 - 118 - - - - 
88. Sudha 20 IV Primi T Oligo - - 27.77 - 111 - - - - 
89. Lakshm 29 IV G2P1L1 T - - - 26.84 - 75 - - - - 
90. Raja 18 IV Primi T Oilgo - - 20.08 - 105 - - - - 
91. Velu 30 III G2P1L1 T - - - 25.86 - 111 - - - - 
92. Radha 22 IV Primi T PROM - - 24.83 - 96 - - - - 
93. Vijaya 28 V G2P1L1 T - - - 26.67 - 150 N - - - 
94. Sumathi 28 IV G2P1L1 T Oligo - - 31.55 - 109 - - - - 
95. Mythili 20 IV G2A1 T Enc - - 19.36 - 109 - - - - 
96. Siranje 27 IV Primi T - - - 23.78 - 85 - - - - 
97. Nalini 22 IV G2P1L1 T - - - 26.29 - 132 - - - - 
98. Dhana 21 IV Primi T - - - 22.18 - 162 N - - - 
99. Ratinam 24 IV G2A1 T - - - 27.84 - 122 - - - - 
100 Stella 32 IV G2P1L1 T Pr CS - - 26.17 - 107 - - - - 
101. Kancha 27 IV Primi T - - - 23.1 - 110 - - - - 
102. Sneha 29 IV G2P1L1 T - PIH F 24.8 - 106 - - - - 
103. Padma 21 IV G2A1 T - - - 26.7 - 98 - - - - 
104. Lakshi 29 IV G2P1L1 T - - - 28.1 - 98 - - - - 
105. Sudha 22 IV G2P1L1 T - - - 21.0 - 94 - - - - 
106. Kavitha 28 IV G2P1L1A1 T - PROM - 36.9 - 100 - - - - 
107. Bhuva 26 V G2P1L1 T - - - 26.3 - 98 - - - - 
108. Mercy 23 III Primi T - - - 24.0 - 104 - - - - 
109. Pinky 29 IV G2A1 T - Oligo - 34.5 - 106 - - - - 
110. Mahila 29 IV G2P1L1A1 T Pr CS - - 27.0 - 110 - - - - 
111. Shantha 29 IV G2P1L1 T - - - 24.8 + 164 N - - - 
112. Nalini 25 III G2P1L1 T - - - 23.1 - 140 N  - - - 
113. Sumaty 22 IV Primi T - Oligo - 24.0 - 148 N - - - 
114. Amuda 24 IV Primi T - - - 23.96 - 148 N - - - 
115. Sagaya 32 IIII G2P1L1 T - PROM - 25.97 - 140 N - - - 
116. Anita 24 III Primi T - Oligo - 23.3 - 146 N - - - 
117. Parmsh 28 III G4P2L2 A1 T - GDM - 26.5 - 150 + N N D
118. Kavitha 32 III G2P1L1 T Pr CS GDM - 29.6 - 148 + N N D
119. Sangeta 22 III G2P1L0 T ND GDM - 26.92 ++ 249 + N ↑ D
120. Rukmai 26 IV G2P1L1 PT - - - 28.2 - 91 - - - - 
121. Anita 19 III G2A1 T - PROM - 23.6 - 100 - - - - 
122. Preeti 27 IV G2A1 T - - F 28.0 - 114 - - - - 
123. Selvam 29 III Primi T - - - 26.5 - 112 - - - - 
124. Priya 19 III Primi T - - - 21.5 - 98 - - - - 
125. Bhuva 27 III Primi T - - - 28.1 - 114 - - - - 
126. Shakita 25 V G2A1 T - - - 25.96 - 94 - - - - 
127. Valar 27 IV G2P1L1 T Pr CS - - 24.88 - 102 - - - - 
128. Judy 21 III Primi T - - - 26.34 - 133 - - - - 
129. Celin 30 IV G3P2L0 T - - - 32.88 - 105 - - - - 
130. Radhai 26 III G3P1L1A1 T Pr CS - - 27.20 - 104 - - - - 
131. Sangeta 18 III G2P1L1 T Pr CS - - 30.78 - 100 - - - - 
132. Synthia 29 V Primi T - - - 21.11 - 126 - - - - 
133. Kala 21 V G2P1L0 T - - - 27.82 - 126 - - - - 
134. Anbu 30 IV G2P1L1 T Pr CS - - 31.24 - 99 - - - - 
135. Srekala 27 IV G2A1 T - - - 24.03 - 128 - - - - 
136. Kowsla 27 IV Primi T - - - 27.47 - 98 - - - - 
137. Shanthi 31 IV G2P1L1 T - - - 26.29 - 100 - - - - 
138 Shanthi 26 IV G2P1L1 T - - - 26.98 - 106 - - - - 
139. Revathy 32 IV G2A1 T HC PIH - 35.15 - 146 N - - - 
140. Vasanta 29 V Primi PT PIH Oligo F 25.75 - 208 N - - - 
141. Gomati 19 IV Primi T - - - 34.23 - 106 - - - - 
142. Jothi 24 IV G2P1L1 T - - - 24.14 - 95 - - - - 
143. Anita 20 IV G3A2 T - - - 21.77 - 100 - - - - 
144. Nisreen 28 IV G2P1L1 T - PROM F 30.01 - 158 N - - - 
145. Lashmi 27 IV G3P1L1A1 T - - - 24.43 - 108 - - - - 
146. Jaya 27 III Primi T - - - 32.32 - 125 - - - - 
147. Kala 25 IV Primi T - - - 26.63 - 108 - - - - 
148. Radhika 19 V Primi T - - - 24.83 - 110 - - - - 
149. Revathi 34 III G2A1 T - PROM - 35.15 - 123 - - - - 
150. Vanitha 22 III  G2A1 T - - - 24.88 - 112 - - - - 
151. Kavitha 23 III Primi T - - - 20.82 - 141 N - - - 
152. Jayanti 23 III P T - - - 18.05 - 101 - - - - 
153. Sathya 21 III P T - - - 29.17 - 128 - - - - 
154. Lumee 23 III P T - PIH - 31.97 - 91 - - - - 
155. Bhaga 20 IV P T - - - 21.11 - 106 - - - - 
156. Sumaty 25 V G3P1L1A1 T Pr CS - - 22.21 - 154 N - - - 
157. Nirmala 33 IV Primi T - - - 23.55 - 106 - - - - 
158. Megala 20 IV Primi T IUGR - - 24.11 - 116 - - - - 
159. Malathi 29 III G3P1L1 T Oligo - - 19.62 - 106 - - - - 
160. Anita 23 IV Primi T - - - 23.83 - 110 - - - - 
161. Vanitha 25 III Primi T - Oligo - 25.87 - 108 - - - - 
162. Kalpana 23 V Primi T - - - 20.56 - 74 - - - - 
163. Jothi 24 IV G3P1L1 T - - - 24.99 - 95 - - - - 
164. Jayanti 22 III Primi T - - - 18.97 - 101 - - - - 
165. Jenita 27 IV G3P1L1 T - - - 28.56 - 108 - - - - 
166. Jayanti 29 III G4P1L1A2 T Pr CS - - 25 - 120 - - - - 
167. Anita 21 V Primi T - - - 25.9 - 117 - - - - 
168. Sakila 24 V G3P1L1 T - - - 23.4 - 108 - - - - 
169. Gayatiri 28 V G2P1L1 T - - - 26.77 - 132 - - - - 
170. Bagya 32 IV Primi T - - PRO
M 
27.74 - 146 N - - - 
171. Amsa 23 III G3P1L1A1 T - - - 25.10 - 124 - - - - 
172. Sarala 20 IV Primi T Pr CS - - 37 - 103 - - - - 
173. Subbu 21 III G3P1L1 PT PIH PIH - 25.56 - 112 - - - - 
174. Karupa 26 V G3P1L1 T Pr CS - - 27.12 - 112 - - - - 
175. Girija 24 IV Primi T - - - 25.78 - 88 - - - - 
176. Vijaya 31 III G3P1L1A1 T - Epile - 27.12 - 152 N N - - 
177. Rajesh 30 V G2P1L1 T - - - 26.56 - 131 N N - - 
178 Surya 31 IV G4P1L1A2 T - - F 28.44 - 152 + N D - 
179. Christi 29 IV G2P1L1 T Pr CS PIH - 36.96 - 158 + N I N
180 Shanthi 26 IV G2P1L0 T IUDPrS - - 32.54 - 192 + N D N
181. Kavitha 23 III Primi T - - F 26.67 - 146 + N D N
182. Uma 30 IV G2P1L1  T Pr CS - - 25 - 110 - - - - 
183. Ranjani 29 III Primi T - - - 23.2 - 110 - - - - 
184. Gomaty 22 V P T - Oligo - 21.05 - 53 - - - - 
185. Sakntal 37 IV G2P1L1 T - - - 23.06 - 94 - - - - 
186. Jaya 24 IV G3P1L1A1 T - - - 21.78 - 99 - - - - 
187. Vidhya 23 III Primi T - - - 35.20 - 109 - - - - 
188. Sumaty 27 IV Primi T - - - 32.46 - 76 - - - - 
189. Vidhya 25 IV G2P1L0 T - - - 22.10 - 92 - - - - 
190. Jayarai 28 V G6P2L1A3 T - FMS - 28.30 - 86 - - - - 
191. Kavitha 28 II Primi T - PROM - 25.96 - 112 - - - - 
192. Hema 28 IV Primi T - - - 26.47 - 110 - - - - 
193. Jaya 24 IV G2P1L1 T - - - 28.12 - 116 - - - - 
194. Dhana 31 V P T - - F 25.74 - 142 N - - - 
195. Thanga 26 IV G2P1L1 T - - - 27.23 - 142 N - - - 
196. Kala 22 IV Primi T - PROM - 25.47 - 120 - - - - 
197. Sathya 20 III Primi T - Oligo - 23.19 - 88 - - - - 
198. Jaya 25 III G2P1L1 T - - M 23.24 - 85 - - - - 
199. Jine 27 III G3P2L2 T - - - 26.15 - 101 - - - - 
200. Chanda 23 III G2P1L0 T ND - - 23.61 - 112 - - - - 
201 Sudha 22 III P T - - - 25 - 120 - - - - 
202. Jothi 28 V G2P1L1 T - - - 26.87 - 98 - - - - 
203. Rohini 26 V G2P1L1 T Pr CS - - 20.81 - 110 - - - - 
204. Jahana 27 II Primi PT - IUD - 28.14 - 133 - - - - 
205. Bhuvan 28 IV G2P1L1 T - - - 26.33 - 117 - - - - 
206. Rajes 28 IV Primi T - - - 27.05 - 87 - - - - 
207. Vijaya 27 IV G2P1L1  T - Oligo - 17.07 - 106 - - - - 
208. Nithya 22 IV G3P1L1A1 T - - - 27.94 - 94 - - - - 
209. Shantha 26 III Primi T - - F 24.12 - 130 - - - - 
210. Kala 23 IV G2P1L1 T Pr CS Oligo - 25 - 112 - - - - 
211. Vennila 25 V G2P1L1 T - - - 20.70 - 124 - - - - 
212. Uma 34 II G2P1L1 T - PIH - 27.12 - 106 - - - - 
213. Sivgami 27 IV Primi T - PROM - 24.28 - 108 - - - - 
214. Stella 29 IV G5P2L1A1 PT Pr CS - - 30.30 - 80 - - - - 
215. Dhana 23 III G2P1L1 PT - PROM - 25.77 - 102 - - - - 
216. Pomani 26 IV G2P1L1 T Pr CS - - 26.75 - 130 - - - - 
217. Meera 28 IV G2P1L1 T Pr CS - - 27.20 - 92 - - - - 
218. Aruna 41 III G8P1L1A6 T - - - 37.94 - 77 - - - - 
219. Vaijaya 33 IV G3P1L1A1 T - - - 28.90 - 164 N - - - 
220. Dhana 25 IV G2P1L1 T - - - 24.17 - 140 N - -  
221. Jaya 30 III G2P1L1 T - PIH+Oli - 36.16 - 140 N - -  
222. Sreeja 27 II G2P1L1 T - PROM - 24.73 - 141 N - -  
223. Vimala 27 II G2P1L1 PT - GDM - 43.41 - 183 + N I ↑ 
224. Thulasi 23 III G2P1L1 T - - - 33.59 - 123 - - - - 
225. Chitra 25 III Primi PT - PIH - 25.91 - 116 - - - - 
226. Nirmala 25 IV G4A3 T - - - 24 - 96 - - - - 
227. Parmes 25 IV Primi T - - - 18.15 - 109 - - - - 
228. Kala 24 IV G2P1L1 T Pr CS - - 24.1 - 104 - - - - 
229. Nithya 22 IV Primi T - Oligo - 21.6 - 108 - - - - 
230. Deepa  24 IV G2P1L1 T - - - 28.37 - 110 - - - - 
231. Sreemat 26 III G2P1L1 PT - - MF 39.6 - 107 - - - - 
232. Bhuva 26 V G4P1L1A2 T - - - 25.10 - 107 - - - - 
233. Kavitha 20 V Primi T - - - 21.09 - 72 - - - - 
234. Vinodh 28 II G2P1L1 T Pr CS - - 21.09 - 121 - - - - 
235. Thilaga 31 IV G3P1L1A1 T Pr CS Oligo - 23.80 - 140 N - - - 
236. Vijaya 24 IV G2A1 T - - - 33.33 - 142 N - - - 
237. Lavana 25 IV G3P1L1A1  T -   GDM - 28.30 - 183 + N D N
238. Leena 31 III G3P1L1A1 T Pr CS - M 25.60 - 149 N - - - 
239. Padma 23 IV Primi T - PIH M 26.17 - 123 - - - - 
240. Vijaya 25 III Primi T - PROM - 29.68 - 97 - - - - 
241. Sophia 29 III Primi T - PROM F 25 - 115 - - - - 
242. Vasanth 30 III G3P1L1A1 T - - - 23.17 - 91 - - - - 
243. Abirami 26 III Primi T - PROM - 22.15 - 91 - - - - 
244. Bhuvan 29 IV G2P1L0 T - - - 25.51 - 84  - - - 
245. Shanthi 29 III Primi T - - - 28.51 - 106 - - - - 
246. Juliet 38 III G3P1L1A1 T - - - 27.73 - 141 N - - - 
247. Praveen 24 II G2P1L1 T - - - 28.01 - 108 - - - - 
248. Muthu 21 IV G2P1L0 T Pr CS - - 26.56 - 123 - - - - 
249. Basmat 30 IV G2A1 T - PROM - 25.31 - 120 - - - - 
250. Radha 21 IV Primi T Rh – - - 28.01 - 104 - - - - 
251. Nithya 24 III G2A1 PT - PTL - 25.31 - 93 - - - - 
252. Sathya 27 IV G2P1L1 T Pr. CS - F 20.73 - 64 - - - - 
253. Faridha 23 IV Primi T - - - 26.49 - 75 - - - - 
254. Uma 28 IV Primi T Rh –- PROM - 24.21 - 85 - - - - 
255. Devi 22 IV Primi T - - - 23.43 - 142 N - - - 
256. Sunitha 27 III Primi T - PIH - 26.38 - 141 N - - - 
257. Supriya 20 III Primi PT - PROM - 17.72 - 81 - - - - 
258. Jaya 21 IV G2A1 T - - - 23.25 - 92 - - - - 
259. Subathr 23 IV Primi T - - - 22.22 - 97 - - - - 
260. Rani 22 IV G3P2L1 T Pr. CS - - 19.53 - 105 - - - - 
261. Rama 23 IV Primi T - PIH M 24.21 - 106 - - - - 
262. Tamil 22 IV Primi T - - - 28.21 - 111 - - - - 
263. Nirma 22 III Primi T - - - 23.01 - 77 - - - - 
264. Devi 25 IV G2P1L1 T - PIH - 32.87 - 92 - - - - 
265. Vasanta 25 IV G3P2L0 T Pr. CS Anen  - 26.56 - 142 N - - - 
266. Saburni 29 V G3P2L2 T - - - 26.78 - 146 N - - - 
267. Priscilla 32 IV Primi T - - - 26.89 - 108 - - - - 
268. Jeenath 19 IV Primi PT - - - 22 - 71 - - - - 
269. Devi 22 III Primi PT - Breec. - 29.77 - 106 - - - - 
270. Jaya 21 IV Primi T - - - 23 - 72 - - - - 
271. Angala 24 III Primi T - - - 22 - 108 - - - - 
272. Hema 31 II Primi T - - M 30.22 - 124 - - - - 
273. Sheeba 25 III G2P1L1 T - - - 26.33 - 95 - - - - 
274. Vanitha 23 III G2P1L1 T Pr.CS - - 26 - 89 - - - - 
275. Naga 27 III G3P2L1 T Pr. CS - - 25.77 - 121 - - - - 
276. Amuda 20 IV Primi T - - - 22.63 - 99 - - - - 
277. Lavan 25 III Primi T - PIH - 25.31 - 98 - - - - 
278. Raja 30 IV G2P1L1 T Pr. CS - - 26.56 - 76 - - - - 
279. Maha 25 II G2P1L1 T  - - - 21.8 - 108 - - - - 
280. Revathy 32 V G2P1L1 T - PROM - 22.35 - 80 - - - - 
281. Roopa 24 IV Primi T - - - 22.22 - 88 - - - - 
282. Latha 31 IV G4P1L1A2 PT - PTL - 33.3 - 120 - - - - 
283. Sushela 30 III Primi T - - - 23.4 - 92 - - - - 
284. Vennila 30 III G2P1L1 T - - - 24.88 - 123 - - - - 
285. Muthu 36 V G2P1L0 T Pr. CS PIH - 22.5 - 80 - - - - 
286. Sumaty 28 III G3A2 T - - F 21.9 - 110 - - - - 
287. Mohana 24 IV G3P2L2 T - - - 23.16 - 108 - - - - 
288. Mahes 32 III Primi T - - M 28.5 - 132 - - - - 
289. Sumaya 23 IV Primi T Rh - - 21.3 - 108 - - - - 
290. Vijaya  19 IV Primi T - - - 23.5 - 108 - - - - 
291. Sasi 27 V G2P1L1 T - - - 31.01 - 109 - - - - 
292. Vanaja 22 III Primi T - - - 21.3 - 117 - - - - 
293. Fasila 24 IV G3P2L2 T - - - 23.93 - 116 - - - - 
294. Uma 20 IV Primi T - - - 21.36 - 117 - - - - 
295. Priya 27 IV G2P1L1 T - - - 29 - 98 - - - - 
296. Kulanda 23 V Primi T - - - 22.0 - 101 - - - - 
297. Leema 30 III G2P1L1 T - - - 28.20 - 128 - - - - 
298. Priya 21 IV Primi T - - - 26.01 - 101 - - - - 
299. I 23 V G2P1L1 T - - - 24 - 76 - - - - 
300. Geetha 28 V G2P1L1 T - - - 26.5 - 114 - - - - 
301. Kavitha 23 V Primi T - - - 23.87 - 61 - - - - 
302. Swetha 25 V G2P1L1 T Rh – - - 29.2 - 26 - - - - 
303. Sumaty 32 IV Primi T - - - 22.45 - 125 - - - - 
304. Thilaga 27 IV G3A2 T - Oligo - 21.24 - 65 - - - - 
305. Neelam 29 IV G3P2L2 T - - - 27.07 - 106 - - - - 
306. Vijaya 23 IV G4P1L1A2 T - - - 31.09 - 100 - - - - 
307. Aruna 23 III Primi T - - - 25.07 - 114 - - - - 
308. Tamil 23 IV G2P1L0 T - - - 20.31 - 134 - - - - 
309. Saras 24 IV Primi T Oligo - - 25.05 - 128 - - - - 
310. Jaya 32 IV G2P1L1 T - - - 24 - 109 - - - - 
311. Deepa 25 III Primi T - Oligo - 27.08 - 94 - - - - 
312. Shantha 28 III G5P1L1A3 T - - - 23.05 - 107 - - - - 
313. Kala 20 IV Primi T - - - 23.05 - 87 - - - - 
314. Shanm  21 III Primi PT - PIH - 23.05 - 134 - - - - 
315. Saroja 21 IV Primi T - PIH - 25.03 - 90 - - - - 
316. Aruna 23 III Primi T - - - 25.04 - 114 - - - - 
317. Hasina 23 IV G2P1L1 T - Bree - 37.36 - 145 N - - - 
318. Latha 26 IV G2A1 T - Oligo - 27.05 - 147 N - - - 
319. Meera 29 III G3A2 T - - F 28 - 145 N - - - 
320. Radha 27 IV G3P1L1A1 T Pr CS - - 25.09 - 162 + N D N
321. Padma 26 IV G2A1 T - PIH - 28.63 - 130 - - - - 
322. Radhika 24 II Primi T - PROM - 25.57 - 122 - - - - 
323. Navane 29 IV G3P1L1A1 T - - - 23.45 - 84 - - - - 
324. Kumdh 31 V Primi T - - - 25.45 - 95 - - - - 
325. Prema 32 IV G3P1L1A1 T - - - 25.28 - 100 - - - - 
326. Gowri 24 IV Primi T - Hydr - 17.77 - 86 - - - - 
327. Maria 23 V G4P1L1A2 T NDAne PTL F 28.76 - 158 N - - - 
328. Kales 22 IV Primi T - GDM - 25 - 146 + N D N
329. Akila 28 IV G2P1L1 T - GDM F 29.77 - 152 + N D N
330. Sridevi 24 III G2A1 T - - - 28.2 - 140 N - - - 
331. Naga 24 IV G2P1L1 PT Pr CS PROM - 29.32 - 101 - - - - 
332. Bhuva 27 III Primi T - PROM F 28.1 - 93 - - - - 
333. Amuda 28 V Primi T - - - 22.22 - 84 - - - - 
334. Kavitha 27 V G4P1L1A2 T - - - 30.83 - 103 - - - - 
335. Vijaya 23 V Primi T - - - 20.48 - 75 - - - - 
336. Yogam 29 IV Primi T - - - 28.69 - 96 - - - - 
337. Revathi 32 IV G2P1L1 T - - M 24.6 - 89 - - - - 
338. Mani 25 III G3P1L1A1 T - Breec - 21.92 - 128 - - - - 
339. Gomaty 24 IV Primi T - - - 27.98 - 117 - - - - 
340. Revathy 22 IV G2P1L1 T - - - 21.94 - 86 - - - - 
341. Geetha 32 III G3P1L1A1 T Pr CS - - 28.57 - 116 - - - - 
342. Nithya 25 II G2A1 T - - - 28.90 - 102 - - - - 
343. Hariha 30 III G3P1L1A1 T - - - 29.00 - 149 N - - - 
344. Anita 25 IV Primi T - - - 25 - 144 N - - - 
345. Rukman 40 IV Primi T PIH - - 31.68 - 140 N - - - 
346. Sabari 26 IV G4A3 T - Se.PIH - 30.91 - 113 - - - - 
347. Jothi 26 IV Primi T PIH - - 35.39 - 111 - - - - 
348. Laksmi 32 V G5P1L1A3 T - PIH - 26.40 - 89 - - - - 
349. Vijaya 29 III G2P1L1 T - - - 31.74 - 121 - - - - 
350. Visalatc  24 III G2P1L1 T - - - 24.90 - 89 - - - - 
351. Kalpana 25 III G3P1L1A1 T - Anae - 23.3 - 146 N - - - 
352. Shanthi 24 III G2P1L0A0 T - Oligo - 24.9 - 140 N - - - 
353. Akila 23 IV Primi T - - - 23.66 - 88 - - - - 
354. Kokila 24 IV G2P1L1A0 T Pr CS - - 25 - 86 - - - - 
355. Nagajoti 21  IV Primi T - Rh – - 18.77 - 97 - - - - 
356. Then 20 III Primi T - PROM - 24.46 - 102 - - - - 
357. Sarojini  33 III Primi T - PIH - 26.47 - 130 - - - - 
358. Tharani  24 III Primi T - - - 22.53 - 75 - - - - 
359. Kokila 19 IV Primi T - - - 25.51 - 102 - - - - 
360. Yasoda 23 IV Primi T - - - 24.2 - 124 - - - - 
361. Krishna 27  IV G2P1L1 T - - - 17.67 - 93 - - - - 
362. Vijaya 24 IV G2A1 T - - - 36.37 - 112 - - - - 
363. Munira 32 III G4P2L2A1 T - - - 25.49 - 58 - - - - 
364. Devani 28 III Primi T - - - 24.30 - 115 - - - - 
365. Helen 26 III Primi T - Oilgo - 23.33 - 81 - - - - 
366. Vadivu 22 III Primi T - PIH M 27.71 - 122 - - - - 
367. Mohana 24 IV G2P1L1 T - - - 16.42 - 90 - - - - 
368. Deepa 24 IV Primi T - - - 25 - 85 - - - - 
369. Siri 26 III Primi T - - - 23.1 - 116 - - - - 
370. Thama 24 III G2P1L0 T IUD - - 25 - 114 - - - - 
371. Archna 19 IV Primi T - Breec - 29.67 - 97 - - - - 
372. Chandr 27 IV G2P1L1 T - - - 26.08 - 81 - - - - 
373. Radh 27  IV G2P1L1 T - PIH - 20.46 - 83 - - - - 
374. Esther  25 IV G2P1L1 T - - - 26.07 - 99 - - - - 
375. Sindhu 27 IV G2P1L1 T - - - 22.23 - 112 - - - - 
376. Laksmi 23 IV G2P1L1 T - - - 23.17 - 108 - - - - 
377. Yasoda 20  IV Primi T - - - 24.47 - 116 - - - - 
378. Rathina 22 V G2P1L1 T - - - 20.08 - 108 - - - - 
379. Mantha 25 IV Primi T - - - 26.33 - 142 - - - - 
380. Petchia 30 IV G4P1L1A2 T - - - 30.37 - 108 - - - - 
381. Sasia 30 IV G4P1L1A2 T Anom GDMPr - 27 - 162 + N D N
382. Balam 23 IV G2P1L0 T SB GDMPI - 20.8 - 148 + N D N
383. Chitra 24 IV G3P1L1A1 T Pr CS - - 23.4 - 101 - - - - 
384. Maha 24 III Primi T - - - 27.34 - 128 - - - - 
385. Sabitha 22 III Primi T - - - 27.01 - 116 - - - - 
386. Amuda 28 III G2P1L1 T Pr CS - - 25.7 - 94 - - - - 
387. Alamu 29 IV Primi T - - - 24.2 - 110 - - - - 
388. Geetha 20 IV Primi T - - M 33.5 - 81 - - - - 
389. Niranja 22 III Primi T - - - 36.7 - 92 - - - - 
390. Shanm 30 III G2P1L1 T - Oligo - 27.3 - 126 - - - - 
391. Kumuta 31 III G3P1L1A1 T Pr CS - - 21.8 - 157 N - - - 
392. Vijaya 30 III Primi T - - - 21.4 - 113 - - - - 
393. Jayanti 30 III G4P1L1A2 T - - - 34.9 - 109 - - - - 
394. Malar 21 IV Primi T - - - 27.3 - 96 - - - - 
395. Selvi 28 III Primi T - - - 28.6 - 87 - - - - 
396. Angelin 29 III Primi T - - - 27.3 - 97 - - - - 
397. Nirmala 37 III Primi T - - - 26 - 80 - - - - 
398. Renuka 24 IV Primi T - PIH M 22.1 - 68 - - - - 
399. Fathima 24 IV G6P3L2A2 T - - - 30.2 - 95 - - - - 
400. Santha 27 III G2P1L1 T Pr CS - - 32.8 - 102 - - - - 
401. Sugana 23 IV G2P1L1 T - - - 25.3 - 111 - - - - 
402. Priya 20 IV G2A1 T - - - 23.1 - 107 - - - - 
403. Megala 23 IV Primi T - Oligo - 26.3 - 85 - - - - 
404. Padma 29 III G2P1L1 T - HIV + - 31.2 - 134 - - - - 
405. Surya 27 IV G2P1L1 T - Breec - 24.8 - 133 - - - - 
406. Parimal 23 III Primi PT - - - 30.8 - 120 - - - - 
407. Kalpana 23 IV Primi T - - - 28.8 - 85 - - - - 
408. Vijaya 25 IV G3P1L0A1 T Pr CS - - 26.6 - 106 - - - - 
409. Savithiri 23 V G2P1L1 T Pr CS - - 23.4 - 75 - - - - 
410. Priya 26 III G2P1L1 T - - - 29.2 - 122 - - - - 
411. Jilidon 32 III G2P1L1 PT - PROM - 36.8 - 164 N - - - 
412. Radha 31 IV Primi T - PIH F 27.4 - 142 N - - - 
413. Jamuna 25 III Primi T - -  - 32.82 - 164 N - - - 
414. Chitra 26 III Primi T - GDM - 28.69 - 153 + ↑ I ↑ 
415. Jothi 26 IV G2P1L0 T ND GDM - 28.6 - 210 + N I N
416. Deepa 26 III Primi T - GDM - 35.1 - 214 + N I N
417. Meena 32 III G2P1L1  T 4.2kg GDM hy MF 31.6 - 180 + N I N
418. Margat 26 V G2A1 T - GDM - 27.2 - 159 + N I N
419. Nalini 24 III Primi T - GDM - 31.1 - 145 + N I N
420. Renu 37 II G2P1L1  T Pr. CS GDM hy - 36.2 - 222 + N D N
421. Balmani 27 IV G4P1L1A2 T - GDM M 32.02 - 142 + N D N
422. Lakhmi 29 IV G3P1L0A1 T PIHIUD GDM M 26.9 - 140 + N D N
423. Prabha 25 IV Primi T - - - 24.4 - 110 - - - - 
424. Sudha 29 III G3P1L1A1 T - PROM - 33.3 - 111 - - - - 
425. Anandi 24 IV Primi T - - - 27.32 - 100 - - - - 
426. Muthu  21 V Primi T - PROM - 21.4 - 87 - - - - 
427. Ponutai 25 IV G2P1L1 PT - - - 23.4 - 100 - - - - 
428. Sindu 19 IV Primi T - Hydra - 24.4 - 74 - - - - 
429. Revathy 26 IV G2P1L0 T BOH - - 25.3 - 110 - - - - 
430. Viola 24 III P T - - F 26.62 - 108 - - - - 
431. Priya 21 IV P T - PROM F 24.1 - 87 - - - - 
432. Kavitha 23 V P PT - - - 23.0 - 90 - - - - 
433. Prema 19 III P T - - - 35.5 - 82 - - - - 
434. Jaisee 31 III P T - - - 28.42 - 82 - - - - 
435. Mahes 22 V Primi T - - - 24 - 135 - - - - 
436. Girija 33 II Primi T Epilep - - 24.4 - 120 - - - - 
437. Nagama 26 V G3P1L1A1 T - - - 27.5 - 128 - - - - 
438. Deepa 23 IV G2P1L1 T PROM - F 25.32 - 120 - - - - 
439. Saras 21 III Primi T - - - 27.02 - 128 - - - - 
440. Shobna  27 IV G2P1L1 T - - - 27.02 - 114 - - - - 
441. Usha 35 III G5P1L1A3 T - - - 24 - 108 - - - - 
442. Jihan 23 III G2A1 PT PIH - - 28 - 100 - - - - 
443. Gowri 20 IV G2P1L1 T - Oligo - 29.3 - 104 - - - - 
444. Firoja 19 IV Primi T - - - 22.4 - 86 - - - - 
445. Kowsik 27 III Primi T - - - 24.6 - 123 - - - - 
446. Joyjona 26 III G2A1 T - - - 21.9 - 80 - - - - 
447. Deepa 21 IV G3A2 T - - - 28.2 - 75 - - - - 
448. Alafia 35 IV G3P2L2 T PIH PIH M 26.4 - 135 + - - - 
449. Sreeba 24 II G3P1L1A1 T - - - 28.4 - 85 - - - - 
450. Kala 22 IV Primi T - - - 21.6 - 113 - - - - 
451. Freeda 34 III G3P1L1A1 T - - - 21 - 124 - - - - 
452. Jaya 21 III Primi T - - - 22.6 - 84 - - - - 
453. Nabisha 37 IV Primi PT - Oligo - 26.4 - 82 - - - - 
454. Leela 27 III Primi T - - - 27.2 - 122 - - - - 
455. Julie 33 IV G5P1L1A3 T - PIH - 31.5 - 131 - - - - 
456. Kiritika 21 V Primi T - - - 23.2 - 77 - - - - 
457. Kalpana 26 III Primi T - Oligo - 25.4 - 118 - - - - 
458. Kasturi 25 III Primi T Rh - - - 31.3 - 108 - - - - 
459. Jothi 23 IV Primi T - PROM - 20.8 - 110 - - - - 
460. Megala 27 III Primi T - - - 27 - 114 - - - - 
461. Janaki 28 IV G3P1L1A1 T - - - 22.4 - 80 - - - - 
462. Aruselvi 27 V G2A1 PT - - - 19.5 - 90 - - - - 
463. Bagya 31 IV G2P1L1 T - - - 22.2 - 93 - - - - 
464. Jasmin 26 IV G3P1L1A1 T - - - 26.1 - 106 - - - - 
465. Baby 25 III G2P1L1 T - - - 23.6 - 117 - - - - 
466. Geetha 32 IV G2P1L1 T Pr CS - - 22.8 - 156 - - - - 
467. Vasant 30 III Primi T - Oligo - 20.9 - 94 - - - - 
468. Pushpa 29 V G2P1L1 T Pr CS - - 25 - 100 - - - - 
469. Sumaya  28 IV G2P1L1 T - - - 25.6 - 74 - - - - 
470. Sameen  26 III Primi T - - F 22.7 - 144 N - - - 
471. Saras 30 V G3P2L1 T IUD - - 32.5 - 140 N - - - 
472. Valar 19 IV Primi T - Oligo - 33 - 111 + - - - 
473. Padma 25 V Primi T Polio - - 27.6 - 83 - - - - 
474. Mahesh 25 IV G4P2L1A1 T PrCSIUD - - 26  118 -    
475. Selva 23 II Primi T - - - 24.8 - 113 - - - - 
476. Rathi 26 IV Primi PT PPROM Breec - 26.7 - 113 - - - - 
477. Radha 23 IV Primi T - - - 24.7 - 82 - - - - 
478. Pushpa 32 III G2P1L1 T - - - 25.9 - 115 - - - - 
479. Asha 30 III G2P1L1 T - PROM - 22.4 - 131 - - - - 
480. Lalitha 24 III G2P1L1 T - OliPIH - 29.2 - 107 - - - - 
481. Iyamuth 23 IV Primi T - - - 27.3 - 70 - - - - 
482. Asraf 25 V G2P1L1 T Pr CS - - 31.6 - 151 N - - - 
483. Selva 26 III Primi T - - F 28.5 - 178 N - - - 
484. Prabha 28 IV Primi T - - - 23.4 - 133 - - - - 
485 Cyron 32 III G2P1L1 T - - - 35.5 - 123 - - - - 
486. Naga 28 II G1P1L1A1 T  - - 27.7 - 122 - - - - 
487. Jaya 22 III Primi T - - - 25 - 118 - - - - 
488. Anitha 21 IV Primi T - Oligo - 22.6 - 108 - - - - 
489. Prema 25 IV Primi T - - M 19.5 - 147 N - - - 
490. Sudha 23 IV G2A1 T - Rh – - 23.4 - 150 N - - - 
491. Tamil 28 IV G2P1L1 T - - - 26 - 77 - - - - 
492. Sridevi 24 IV G2P1L1 T - - - 28.3  100 - - - - 
493. Lilly 20 IV Primi T - - - 26 - 108 - - - - 
494. Jaba 21 V Primi T - - - 27 - 110 - - - - 
495. Kalpana 22 IV Primi T - - - 22.4 - 108 - - - - 
496. Rahda 23 IV Primi T - - - 24 - 106 - - - - 
497. Ananta 29 IV G2A1 T - - - 22 - 142 N - - - 
498. Vasanta 27 III G2P1L1 T - - - 21.2 - 112 - - - - 
499. Mahes 19 IV Primi T - - - 23 - 108 - - - - 
500. Vidhya 23 III Primi T - GDM  Oli F 26 - 148 + N D - 
501. Mani 29 III G2P1L1 T - - - 23.2 - 112 - - - - 
502 Prema 33 IV G2P1L1 T - - - 24.1 - 106 - - - - 
 
Lost for followup 
 
503. Kamala 25 III G2P1L1 T - - - 23.6 - 117 - 
504. Vimala 32 IV G2P1L1 T Pr CS - - 22.8 - 156 - 
505. Vasant 30 III Primi T - - - 20.9 - 94 - 
506. Rani 29 V G2P1L1 T Pr CS - - 25 - 100 - 
507. Jeni  28 IV G2P1L1 T - - - 25.6 - 74 - 
508. Sheeba  26 III Primi T - - F 22.7 - 144 N 
509. Chitra 21 IV G3A2 T - - - 28.2 - 75 - 
510. Vimala 35 IV G3P2L2 T PIH - M 26.4 - 135 + 
511. Kala 24 II G3P1L1A1 T - - - 28.4 - 85 - 
512. Selvi 22 IV Primi T - - - 21.6 - 113 - 
513. Rani 34 III G3P1L1A1 T - - - 21 - 124 - 
514. Vijaya 21 III Primi T - - - 22.6 - 84 - 
515. Mani 37 IV Primi PT - - - 26.4 - 82 - 
516. Neela 27 III Primi T - - - 27.2 - 122 - 
517. Jenny 33 IV G5P1L1A3 T -       - - 31.5 - 131 - 
518. Kavitha 21 V Primi T - - - 23.2 - 77 - 
519. Kalpana 26 III Primi T - - - 25.4 - 118 - 
520. Revathy 25 III Primi T Rh - - - 31.3 - 108 - 
521. Jothi 23 IV Primi T - - - 20.8 - 110 - 
522. Megala 27 III Primi T - - - 27 - 114 - 
523. Janaki 28 IV G3P1L1A1 T - - - 22.4 - 80 - 
524. Selvi 27 V G2A1 PT - - - 19.5 - 90 - 
 
Key words: 
 
SES – Socio economic status     IUGR  -
 Intra uterine growth restriction 
T  – Term       EMS  -
 Emergency caeserean section 
PT  -  Preterm        ELS  -
 Elective caeserean section  
Oligo  – Oligohydramnios      N  -
 Normal 
Hydra - Hydramnios       D  -
 Diet 
GDM - Gestational diabetes mellitus    I  - Insulin 
Pr. CS - Previous caeserean section    V  - Vaginal 
delivery  
BOH - Bad obstetrics history     V-V  -
 Vaccum 
PIH - Pregnancy induced hypertension   ATF  - Axis 
traction forceps 
PROM- Pre labour rupture of membranes    I  - Induced  
F - Father       S  -
 Spontaneous 
M - Mother       HB  -
 Hyperbilirubinaemia 
GCT - Glucose challenge test    HG  -
 Hypoglycaemia 
GTT - Glucose tolerance test     RDS  -
 Respiratory distress syndrome 
TTN - Transient tachypnoea of newborn   Asphy. - Birth Asphyxia 
LGA - Large for gestational age     SGA  -
 Small for gestational age 
GA - Gestational age      BMI  - 
 Bodymass index 
Anen. - Anencephaly       HC  -
 Hydrocephaly 
ND - Neonatal death      SB  -
 Still birth 
Anom – Anomalous baby       PTL  -
 Preterm labour 
